Page last updated: 2024-08-18

thiophenes and Stroke

thiophenes has been researched along with Stroke in 393 studies

Research

Studies (393)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's38 (9.67)29.6817
2010's347 (88.30)24.3611
2020's8 (2.04)2.80

Authors

AuthorsStudies
Ahmed, HA; Alshammari, A; Althomali, W; Awad, ME; Cooley, MA; Dong, G; Eldahshan, W; Elsalanty, M; Ergul, A; Fagan, SC; Gillis, E; Jackson, L; Pillai, B; Sayed, MA; Sullivan, JC1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Carnicelli, AP; Fox, KAA; Halperin, JL; Hankey, GJ; Hellkamp, AS; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE1
Ding, HY; Jiao, Z; Liu, XQ; Ma, CL; Yan, MM; Zhang, YF; Zhong, MK1
Ahmed, HA; Devlin, P; Ishrat, T; Ismael, S; Liao, FF; McDonald, MP; Salman, M1
Ahmed, HA; Ergul, A; Fagan, SC; Fouda, AY; Hardigan, T; Ishrat, T; Kozak, A; Pillai, B1
Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z1
Takahashi, T1
Althomali, W; Baban, B; Dong, G; Eldahshan, W; Ergul, A; Fagan, SC; Filosa, J; Jackson, L; Johnson, MH; Sayed, MA1
Yavelov, IS1
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z1
Fang, X; Ni, HF; Tong, KZ; Wang, X1
Chen, G; Chen, X; Cheng, Y; Cui, Y; Cui, Z; Li, P; Li, Q; Liu, Z; Yao, L; Zhang, F; Zhang, K; Zhang, N; Zhang, S1
Hu, Y; Huang, S; Tang, L1
Bennion, DM; Dang, AN; Domenig, O; Graham, JT; Isenberg, J; Jones, CH; Lindblad, L; Poglitsch, M; Steckelings, UM; Sumners, C; Waters, MF1
Ahmed, H; Eldahshan, W; Ergul, A; Fagan, SC; Fouda, AY; Ishrat, T; Pillai, B; Waller, JL1
Abe, H; Goshima, Y; Higo, N; Jitsuki, S; Jitsuki-Takahashi, A; Katsuno, Y; Komori, T; Masuyama, H; Mochizuki, N; Murata, Y; Nakajima, W; Okuda, T; Sano, A; Suyama, K; Tada, H; Takahashi, T1
Buse, JB; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Mellbin, L; Neal, B; Nicholls, SJ; Nozza, A; Rydén, L; Schrieks, IC; Schwartz, GG; Stähli, BE; Svensson, A; Tardif, JC; Wedel, H; Weichert, A1
Ahmed, HA; Bunting, KM; Ergul, A; Fagan, SC; Ishrat, T; Pillai, B; Vazdarjanova, A; Waller, JL1
Anticoli, S; Dalmaso, SG; Marchitto, N; Pannozzi, A; Raimondi, G; Sindona, F1
Boujon, V; Endres, M; Gertz, K; Kronenberg, G; Laufs, U; Uhlemann, R; Wegner, S; Wright, MB1
Barrios, V; Escobar, C1
Akwaa, F; Spyropoulos, AC1
Galanis, T; Merli, GJ1
Berman, JP; Halperin, JL1
Lenchus, JD1
Apostolakis, S; Kasmeridis, C; Lip, GY1
Hernández, M; Suárez, C1
Masjuan, J1
Dalmau, FG1
Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR1
Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Pan, G; Patel, MR; Piccini, JP; Singer, DE1
Armstrong, EP; Harrington, AR; Malone, DC; Nolan, PE1
Chen, W; Geng, Y; Hu, XY; Wei, LL; Yao, LY; Zhang, JH; Zhang, LS1
Badimón, JJ; Briongos Figuero, S; García Santos-Gallego, C1
Cayabyab, FS; Gowribai, K; Walz, W1
Harris, K; Mant, J1
Atarashi, H1
Darius, H; Sommer, S1
Ahmad, Y; Lip, GY2
Gallego, P; Lip, GY; Roldan, V1
Carter, NJ; Plosker, GL1
Aisenberg, J; Desai, J; Kolb, JM; Weitz, JI1
Bauer, KA1
Aisenberg, J; Desai, J; Granger, CB; Weitz, JI1
Klein, HH1
Toth, PP1
Apostolakis, S; Lip, GY; Shantsila, E1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hannan, KL; Hellkamp, AS; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Schwabe, K; Singer, DE1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; White, HD; Wojdyla, D1
Gong, IY; Kim, RB1
Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA1
Boos, CJ; Camm, AJ; Nam, M1
Finsterer, J; Stöllberger, C5
Diener, HC1
Lopes, RD; Newby, LK; Truffa, AA1
Bhimani, AA; Hong, M1
Geller, BJ; Gibson, CM; Guo, J; Hoffman, EB; Mega, JL; Morrow, DA; Ruff, CT1
Opolonskaia, NA; Tseluĭko, VI; Vashakidze, ZS1
Kamal, AK; Kamran, SH; Muzammil, SM1
Amin, A; Deitelzweig, S; Graham, J; Jing, Y; Lin, J; Makenbaeva, D; Wiederkehr, D2
Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M1
Aguilar, MI; Freeman, WD; Kuo, RS1
Delgado-Fernández, M1
Hori, M; Kajikawa, M1
Dalen, JE1
Fanikos, J1
Li, C; Li, T; Mao, L; Yuan, K1
Wanat, MA1
Baglin, T1
Stiefelhagen, P1
Barry, M1
Armstrong, PW; Bhatt, DL; Boden, WE; Clemmensen, P; Fox, KA; Hafley, G; Hamm, C; Leiva-Pons, J; Lokhnygina, Y; Menozzi, A; Nicolau, JC; Ohman, EM; Oto, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; White, HD; Widimsky, P; Winters, KJ; Wiviott, SD1
Lip, GY; Potpara, TS1
Diener, HC; Easton, JD; Hankey, GJ; Hart, RG1
Barco, S; Cheung, YW; Coppens, M; Eikelboom, JW1
Kansal, AR; Pokora, T; Sorensen, SV; Zheng, Y1
Goto, S; Hori, M; Iekushi, K; Izumi, T; Kajikawa, M; Kato, M; Koretsune, Y; Matsumoto, M; Momomura, S; Tajiri, M; Tanahashi, N; Uchiyama, S; Ueda, H; Yamanaka, S1
Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G1
Buse, JB; Cannata, R; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Neal, B; Nicholls, SJ; Rydén, L; Schwartz, GG; Tardif, JC; Wedel, H; Weichert, A1
Apostolakis, S; Banerjee, A; Lane, DA1
Becker, RC; Breithardt, G; Califf, RM; Chang, Y; Fox, KA; Go, AS; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR2
Brunkhorst, R; Foerch, C; Lindhoff-Last, E; Luger, S; Pfeilschifter, W1
Asukai, Y; De Ruyck, M; Evers, T; Faes, P; Goethals, M; Kleintjens, J; Li, X; Rietzschel, ER; Saka, Ö; Simoens, S; Thijs, V; Vansieleghem, S1
He, B; Kun, L; Liu, X; Wu, B1
Hughes, DA; Lane, S; Pink, J; Pirmohamed, M1
Gunalingam, B; Markus, R; Spina, R; Subbiah, R1
Kornej, J; Lip, GY; Potpara, T1
Anisimova, AV; Borisov, SN; Gendlin, GE1
Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR; White, HD1
Liberato, NL; Marchetti, M; Quaglini, S; Rognoni, C1
Eikelboom, JW; Kapral, MK; McGrath, ER; O'Donnell, MJ1
Nagatsuka, K; Okata, T; Takasugi, J; Toyoda, K; Yamagami, H1
Alonso-Canovas, A; Alvarez-Velasco, R; de Felipe Mimbrera, A; Kawiorski, MM; Masjuan, J; Sainz de la Maza, S; Zarza, B1
Wood, P1
Antman, EM; Bates, ER; Mega, JL; Murphy, SA; O'Donoghue, ML; Ojeifo, O; Sabatine, MS; Udell, JA; Wiviott, SD1
Manning, JA1
Kitazono, T1
Uchiyama, S1
Laffan, M; Shapiro, S1
Breithardt, G; Califf, RM; Fox, KA; Halperin, J; Hankey, GJ; Hellkamp, AS; Jones, WS; Mahaffey, KW; Patel, MR; Piccini, JP; Singer, DE1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Sherwood, MW; Singer, DE; White, HD; Wojdyla, DM1
Heitmeier, S; Jenetzky, E; Ploen, R; Sun, L; Veltkamp, R; Zhou, W; Zorn, M1
Baker, R; Herrmann, R; Muhammad, S; Phillips, M; Thom, J; Wood, A1
Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M1
Angiolillo, DJ; Antoniucci, D; Bernlochner, I; Hamm, C; Jaitner, J; Kastrati, A; Laugwitz, KL; Mayer, K; Morath, T; Neumann, FJ; Richardt, G; Ruf, J; Schömig, G; Schühlen, H; Schulz, S; Schunkert, H; von Merzljak, B1
Barillari, G; Cheng, JW1
Archeval-Lao, JM; Bowry, R; Cai, C; Fraser, S; Grotta, JC; Parker, SA; Rahbar, MH1
Diener, HC; Weber, R1
Caldeira, D; Costa, J; Ferreira, JJ; Pinto, FJ1
Bajorek, B; Wang, Y1
Schulman, S1
Berrut, G; Chevalet, P; De Decker, L; Gegu, M; Piloquet, FX1
Hanon, O1
Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A1
Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H1
Bennion, DM; Desland, F; Joseph, JP; Katovich, MJ; Mecca, AP; Patel, NA; Pioquinto, DJ; Regenhardt, RW; Rodríguez, V; Steckelings, UM; Sumners, C; Unger, T1
Gnall, EM; Ice, DS; Kowey, PR; Shapiro, TA1
Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ1
Becker, RC; Califf, RM; Douketis, JD; Fox, KA; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Sherwood, MW; Singer, DE; Spyropoulos, AC1
Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Paikin, JS1
Crowther, M; Pasierski, T; Undas, A; Windyga, J1
Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F3
Behrens, L; Capper, D; Purrucker, JC; Veltkamp, R1
Gonzva, J; Lignac, D; Patricelli, R1
Bode, C; Haas, S; Norrving, B; Turpie, AG1
Cloutier, M; Coleman, CI; Damaraju, CV; Laliberté, F; Lefebvre, P; Nelson, WW; Olson, WH; Pilon, D; Schein, JR1
Meddahi, S; Samama, MM1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Garg, J; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE1
Giugliano, RP; Reddy, P1
Buse, JB; Cannata, R; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Neal, B; Nicholls, SJ; Rydén, L; Schwartz, GG; Svensson, A; Tardif, JC; Volz, D; Wedel, H; Weichert, A1
Thachil, J1
Hagen, G; Klemp, M; Wisløff, T1
Hagii, J; Hitomi, H; Kamada, T; Kimura, Y; Metoki, N; Okumura, K; Osanai, T; Saito, S; Shiroto, H; Tomita, H; Yasujima, M1
Piccini, JP; Steinberg, BA1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Halperin, JL; Hankey, GJ; Harrell, FE; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE1
Germain, G; Laliberté, F; Lefebvre, P; Nelson, WW; Olson, WH; Pilon, D; Raut, MK; Schein, JR2
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, R; Fox, KA; Hacke, W; Hankey, GJ; Hu, DY; Mahaffey, KW; Oomman, A; Patel, MR; Singer, DE; Tan, RS; Wong, KS1
Lip, GY; Yasaka, M1
Davidson, N; Galloway, SW; Lai, A; Thachil, J1
Brouns, R; De Keyser, J; De Smedt, A; Jochmans, K; Nieboer, K; van Hooff, RJ; Yperzeele, L1
Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T1
Foley, J; Kirchhof, P; Lip, GY1
Avorn, J; Brennan, TA; Brill, G; Choudhry, NK; Desai, NR; Krumme, AA; Matlin, OS; Pezalla, EJ; Schneeweiss, S; Shrank, WH; Spettell, CM1
Hürlimann, D; Noll, G; Noll, S1
Corelli, K; Ezekowitz, MD; Ghosh, P; Spahr, J1
Chen, H; Higashino, H; Jin, D; Li, W; Miyazaki, M; Okamura, H; Takai, S; Yamamoto, H; Yamanishi, H; Yamanishi, K1
Freedman, JE; Gersh, BJ1
Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE; Wojdyla, DM1
Coleman, CI; Damaraju, CV; Nelson, WW; Schein, JR; Smith, DM; Song, X; Thomson, E1
Lévy, S1
Baker, WL; Chamberlin, KW1
Curnow, J; Joseph, J; McLintock, C; McRae, S; Nandurkar, H; Tran, H; Wood, P; Young, L1
Dan, GA; Kaski, JC; Martínez-Rubio, A1
Angeli, F; Lip, GY; Reboldi, G; Verdecchia, P1
Abe, K; Deguchi, K; Hishikawa, N; Kono, S; Kurata, T; Omote, Y; Sato, K; Yamashita, T; Yunoki, T1
Chatterjee, S; Ghosh, J; Giri, JS; Mukherjee, D; Sardar, P1
Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R1
Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z1
Gerona, RR; Lo, JC1
Chatterjee, S; Halperin, JL; Herzog, E; Mukherjee, D; Nairooz, R; Sardar, P1
Baba, Y; Hagii, J; Hitomi, H; Iwata, M; Kamada, T; Matsumoto, S; Metoki, N; Okumura, K; Osanai, T; Saito, S; Sasaki, S; Seino, S; Shiroto, H; Takahashi, K; Tomita, H; Uchizawa, T; Yasujima, M1
Amarenco, P; Camm, AJ; Haas, S; Hess, S; Kirchhof, P; Turpie, AG; van Eickels, M1
Mitchell, AR; Page, PL; Thomas, R1
Bongu, NR; Kocheril, AG; Turagam, MK; Velagapudi, P1
Black, DF; McBane, RD; Moder, KG; Schaefer, JK; Williams, LN; Wysokinski, WE1
Bonati, LH; Engelter, ST; Gensicke, H; Lyrer, P; Peters, N; Seiffge, DJ; Traenka, C; Tsakiris, DA1
Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N1
Guo, X; Li, L; Tang, B; Xu, G; Zhang, Y; Zhou, X1
Steurer, J1
Bang, OY; Chung, CS; Kim, GM; Kim, JS; Kim, SJ; Lee, KH; Lee, MJ; Park, YK; Ryoo, S; Yoon, CH1
Baumgartner, H; Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR1
Fukae, J; Higashi, T; Inoue, T; Iwaasa, M; Kimura, S; Ogata, T; Okawa, M; Tsuboi, Y1
Rudakova, AV; Tatarskiĭ, BA1
Dobesh, PP; Trujillo, T1
Camm, AJ; Cappato, R; Ezekowitz, MD; Hemmrich, M; Hohnloser, SH; Kirchhof, P; Klein, AL; Lanius, V; Le Heuzey, JY; Ma, CS; Meng, IL; Scanavacca, M; Talajic, M; van Eickels, M; Vardas, PE; Wildgoose, P1
Lane, DA; Lip, GY; Senoo, K1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Steinberg, BA1
Fosbøl, EL; Gislason, GH; Hansen, ML; Køber, L; Lamberts, M; Mikkelsen, AP; Olesen, JB; Sørensen, R; Torp-Pedersen, C; Weeke, P1
Demulder, A; Safouris, A; Triantafyllou, N; Tsivgoulis, G1
Giugliano, RP; Plitt, A1
Madhusudhana, S; Qasem, A; Strasser, KM1
Lamichhane, D1
Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S1
Kovács, T1
Ko, Y; Kong, MC; Lee, LH; Ng, HJ; Wang, Y; Xie, F1
de Boer, A; Hasrat, F; Maitland-van der Zee, AH; Redekop, WK; Verhoef, TI1
Ezekowitz, MD; Kent, AP1
Berghold, A; Kemperdick, B; Mergenthal, K; Petersen, JJ; Rauck, S; Roehl, I; Schulz-Rothe, S; Siebenhofer, A; Ulrich, LR1
Choi, YJ; Hong, KS; Kwon, SU1
Mima, Y; Nagata, S; Okada, Y; Sangatsuda, Y; Wakugawa, Y; Yasaka, M1
Baber, U; Mastoris, I; Mehran, R1
Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R1
Bell, AD; Douketis, J; Eikelboom, J; Liew, A3
Rondina, M1
Greco, C1
Cairns, JA; Weitz, JI1
Feuerstein, JD; Ketwaroo, GA; Leffler, DA; Patwardhan, VR; Sengupta, N; Tapper, EB; Thaker, AM1
Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD1
Dublanchet, N; Dutheil, F; Lebreton, A; Milhaud, G; Moustafa, F; Schmidt, J1
Arepally, GM; Ortel, TL1
Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB1
Merli, GJ; Weitz, HH1
Trusler, M1
Angaran, P; Bell, AD; Berall, M; Bucci, C; Demchuk, AM; Essebag, V; Goldin, L; Goodman, SG; Green, MS; Gregoire, JC; Gross, PL; Heilbron, B; Lin, PJ; Patel, AD; Ramanathan, K; Skanes, A; Tan, MK; Wheeler, BH1
Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR; Washam, JB1
Hogg, K; Weitz, JI; Yeh, CH1
Lane, DA; Wood, K1
Bambakidis, NC; Barnett, A; Filichia, E; Jin, Y; Luo, Y; Raviv, N1
Hilpert, U1
Ay, C; Belik, S; Griesmacher, A; Königsbrügge, O; Pabinger, I; Quehenberger, P; Seger, C; Weigel, G1
Bengus, M; Califf, R; Ditmarsch, M; Erdmann, E; Gerstein, HC; Malmberg, K; Ruilope, L; Schwartz, GG; Svensson, A; Volz, D; Wedel, H1
Botto, GL; Colonna, P; Troccoli, R1
Ichijo, M; Ishibashi, S; Li, F; Miki, K; Mizusawa, H; Yokota, T; Yui, D1
Ofosu, FA1
Lasek-Bal, A; Piekarski, M; Puz, P; Urbanek, T1
Brown, DA; Chang, FL; Curfman, ET; Kuo, PC; Paraiso, HC; Scofield, BA; Yen, JH; Yu, IC1
Alberts, MJ; Hanley, DF; Serebruany, VL1
Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD1
Spyropoulos, AC1
Culebras, A; Kelly, JJ1
Haas, S1
Doggrell, SA1
Calderone, A; Gillis, MA; Gutkowska, J; Jankowski, M; Menaouar, A; Mukaddam-Daher, S; Paquette, PA; Shi, YF; Tardif, JC1
Antman, EM; Brandt, JT; Braunwald, E; Close, SL; Hockett, RD; Macias, WL; Mega, JL; Sabatine, MS; Shen, L; Walker, JR; Wiviott, SD1
Dowlatshahi, D; Hill, MD1
Avery, A; Boyd, EA; Brunton, SA; Buxton, D; di Lucrezia, R; Guicherit, OM; Kruse, LI; MacKinnon, CH; Park, Y; Price, S; Rubin, LL; Stibbard, JH1
Diener, HC; Gradl, B; Greiner, W; Jönsson, B; Lindgren, P; Lüders, S; Schrader, J; Schwander, B; Villar, FA; Zöllner, Y1
Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A1
Antman, EM; Braunwald, E; Finkelstein, A; Fridrich, V; McCabe, CH; Murphy, SA; O'Donoghue, M; Penny, WF; Sabatine, MS; Steg, PG; Wiviott, SD1
Collet, JP; Montalescot, G1
Hasegawa, Y; Rolland, W; Sozen, T; Suzuki, H; Zhang, JH1
Lai, CH1
Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S1
Khalabuda, M; McBride, BF; Morell, J; Sullivan, B1
Serebruany, V2
Lopes, RD; Mahaffey, KW; Piccini, JP1
Diamond, GA; Kaul, S1
Pakhomov, IaM1
Alban, S; Völler, H; Westermann, D1
Finnerup, NB1
Baumhäkel, M; Böhm, M; Schirmer, SH1
Dijkgraaf, MGW; Heesen, M; Hollmann, MW; Kruis, MR; Pijl, AJ; van der Vegt, MH; Vos, K; Vranken, JH1
Weitz, JI1
Mitka, M2
Aumiller, J1
Ahrens, I; Lip, GY; Peter, K1
Eikelboom, JW; Eriksson, BI; Quinlan, DJ1
Ageno, W; Romualdi, E1
Braunwald, E; Steffel, J1
Easton, JD1
Ajzenberg, N; Dumont, B; Faille, D1
Alexopoulos, D; Davlouros, P; Dimitropoulos, G; Hahalis, G; Mylona, P; Panagiotou, A; Perperis, A; Tsigkas, G; Xanthopoulou, I1
Brott, BC; Dobbs, JC; Hillegass, WB; Misra, VK; Papapietro, SE; Zoghbi, GJ1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Garg, J; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Pan, G; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE1
Büller, HR; Eerenberg, ES; Kamphuisen, PW; Sijpkens, MK; van Es, J1
Mega, JL1
Becker, RC; Califf, RM; Fox, KA; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE; Wojdyla, D1
Mousa, SA1
Agnelli, G; Decousus, H; Lensing, AW; Misselwitz, F; Mueck, W; Prandoni, P1
Camaioni, E; Chen, Y; Chiarugi, A; Cozzi, A; Formentini, L; Gonzales, C; Liang, S; Moroni, F; Pellegrini-Giampietro, DE; Pellicciari, R; Wood, A; Zaleska, MM1
Bode, C; Diener, HC; Kaeufer, T1
Leibowitz, A; Paradis, P; Rautureau, Y; Rehman, A; Schiffrin, EL; Yamamoto, N1
Banerjee, A; Lane, DA; Lip, GY; Torp-Pedersen, C1
Abu-Fadel, MS; Dib, C; Golwala, H; Tafur, A1
Nagao, T1
Biller, J; Flaster, M; Morales-Vidal, S; Schneck, MJ1
Parma, Z; Syzdół, M; Tendera, M1
Bergmann, P; Body, JJ; Boonen, S; Devogelaer, JP; Gielen, E; Goemaere, S; Kaufman, JM; Reginster, JY; Rozenberg, S1
Alpert, JS1
Lip, GY; Riva, N1
Gorelick, PB1
Becker, RC; Breithardt, G; Califf, RM; Carolei, A; Diener, HC; Donnan, GA; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Mas, JL; Massaro, A; Nessel, CC; Norrving, B; Paolini, JF; Patel, MR; Roine, RO; Singer, DE; Stevens, SR; Wong, L1
Palareti, G; Tripodi, A1
Bryer, A1
Eisenberg, MJ; Filion, KB; Grandi, SM; Miller, CS; Shimony, A1
Haas, S; Schellong, SM; Spannagl, M1
Gibson, CM; Gopalakrishnan, L; Kohli, P; Kumar, V; Rastogi, U; Singh, P1
Bommer, WJ1
Halperin, JL; Varughese, CJ1
Lewalter, T1
Anglade, MW; Coleman, CI; Kluger, J; Lee, S; Pham, D; Pisacane, R1
Goto, S; Hori, M; Iwamoto, K; Izumi, T; Kajikawa, M; Kato, M; Koretsune, Y; Matsumoto, M; Momomura, S; Tajiri, M; Tanahashi, N; Uchiyama, S; Ueda, H3
Ismael, AG; Ribowsky, JH1
Vivancos Mora, J; Ximénez-Carrillo Rico, A; Zapata Wainberg, G1
Licina, MM; Lip, GY; Polovina, MM; Potpara, TS; Prostran, MS; Stojanovic, RM1
Ansell, J; Mantha, S1
Ball, DG; Day, AG; Gibbens, SL; LaHaye, SA; Olesen, JB; Skanes, AC1
Cohen, D; Gorgoraptis, N; Greenwood, R; Hadji-Michael, M; Husain, M; Kulinskaya, E; Machner, B; Mah, YH; Malhotra, P; Nair, A; Simister, R; Singh-Curry, V; Ward, N1
Agnifili, M; Bedogni, F; Brambilla, N; De Marco, F; Lanotte, S; Latib, A; Latini, RA; Laudisa, ML; Mattioli, R; Oreglia, J; Pizzocri, S; Testa, L1
Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S1
Pollack, CV1
Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY1
Fareed, J; Kalodiki, E; Lewis, B1
Diener, HC; Harenberg, J; Lip, GY; Marder, VJ; Marx, S; Wehling, M; Weiss, C1
Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Moia, M; Palareti, G; Pengo, V; Poli, D; Siragusa, S; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A1
Ji, H; Lai, Y; Li, T; Ling, J; Liu, J; Peng, S; Tian, J; Wang, X; Wu, J; Zhang, Y1
Berthold, HK1
Atar, D; Serebruany, VL1
Zhang, S1
Yasaka, M1
Destephan, C; Dhruvakumar, S; Gerula, C; Kaluski, E; Maher, J; Mazza, V; Patel, RJ; Waller, AH1
Ahrens, I; Bode, C1
Griffiths, M; Scully, C1
Jin, M; Kamrul, R; Kosar, L; Schuster, B1
Cannon, CP; Kohli, P1
Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV1
Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ1
Lyrer, P; Nedeltchev, K; Seiffge, D1
Douketis, JD; Gerotziafas, G; Kaatz, S; Ortel, TL; Schulman, S; Spyropoulos, AC1
Kopecky, S1
Brouwers, PJ; Kappelle, LJ; Koudstaal, PJ; Roos, YB; van Dijk, EJ1
Haas, S; Kreutz, R; Llau, J; Norrving, B; Turpie, AG1
Rajappan, K1
Esmon, CT1
Le Heuzey, JY1
Eikelboom, JW; Manolakos, JJ; Paikin, JS1
Graf, L; Tsakiris, DA1
Karaiskos, D; Paparrigopoulos, T; Spengos, K; Tzavellas, E; Vassilopoulou, S1
Becker, RC; Chan, MY; Cyr, D; Kajikawa, M; Lin, M; Lucas, J; Moseley, A; Ortel, TL; Thompson, JW; Ueda, H1
Sanaei, O1
Koziński, M; Kubica, A; Kubica, J; Navarese, EP; Obońska, K1
Aalbers, J1
Valle Bernad, R1
Blanco-Molina, A1
Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C1
Lipták, J1
Graungaard, T; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F1
Lazo-Langner, A; Sun, D1
Dabitz, R; Ochs, G1
Boehlen, F; de Moerloose, P1
Aradi, D; Komócsi, A; Serebruany, VL; Vorobcsuk, A1
Cohen, DJ; Jones, PG; Li, Y; Salisbury, AC; Spertus, JA; Wang, K1
Martin, EN; Money, SR; Shamoun, FE1
Coccheri, S; Orlando, D1
Li, HF; Zhao, RL1
Medvegy, M; Simonyi, G1
Deitelzweig, SB1
Eraso, LH; Merli, GJ; Perez, A1
Camm, AJ; Savelieva, I1
Greenspon, AJ1
Ganetsky, V; Spinler, SA; Thomas, TF1
Shiga, T1
Grove, EL; Husted, SE; Kraglund, KL; Modrau, B1
Brem, E; Foran, M; Koyfman, A1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Mohanty, S; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Zhang, Z1
Reynolds, MR1
Contractor, T; Levin, V; Marchlinski, FE; Martinez, MW1
Boĭko, AN; Gusev, EI; Makarov, AN; Martynov, MIu; Petukhov, EB1
Berger, J; Diener, HC; Dominiak, P; Hammersen, F; Kulschewski, A; Lüders, S; Plate, K; Schrader, J; Zidek, W1
Basile, J; Bloch, MJ1
Boulanger, JM; Hill, MD1
Strauss, MH; Verma, S1
Boysen, G; Hornnes, N; Larsen, K1
Johnston, SC1
de la Sierra, A1
Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD1
Ram, CV; Rudmann, MA1
Shlyakhto, E1
Rupp, H1
Califf, RM; Fox, KA; Mahaffey, KW; Patel, MR; Piccini, JP1
Alvarez, W1
Cregan, E; Macdonald, JE; McCarthy, DJ; Reif, DW1
Chapman, DF; Lapchak, PA; Zivin, JA1
Asahi, K; Asahi, M; del Zoppo, GJ; Fini, ME; Jung, JC; Lo, EH1
Barone, FC; Brooks, DP; Campbell, WG; Chandra, S; Coatney, RW; Contino, LC; Nelson, AH; Ohlstein, EH; Sarkar, SK; Willette, RN1
Abrahamsen, CT; Barone, FC; Brooks, DP; Campbell, WG; Contino, LC; Edwards, RM; Grygielko, ET; Laping, NJ; Nelson, AH; Pullen, MA1

Reviews

143 review(s) available for thiophenes and Stroke

ArticleYear
    Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227

    Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, Physiological; Adipates; Administration, Oral; Adolescent; Adrenal Glands; Adsorption; Adult; Aged; Aged, 80 and over; Aging; AIDS-Related Opportunistic Infections; Aldosterone; Amino Acids; Ammonia; Amoxicillin; AMP-Activated Protein Kinases; Animals; Antacids; Anti-Bacterial Agents; Antineoplastic Agents; Antirheumatic Agents; Apgar Score; Area Under Curve; ARNTL Transcription Factors; Arterial Pressure; Arthritis, Juvenile; Athletes; Attention; Biodegradation, Environmental; Biofilms; Biofuels; Biological Therapy; Biomass; Biomimetic Materials; Bioreactors; Birth Weight; Bismuth; Blood Flow Velocity; Bone and Bones; Brain Injuries, Traumatic; Calcium; Calcium Channels; Capsaicin; Carbon; Carcinoma, Hepatocellular; Cardiomegaly, Exercise-Induced; Cartilage; Cartilage, Articular; Case-Control Studies; Catalysis; Cats; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Charcoal; Chemokine CCL2; Child; Child, Preschool; Chondrogenesis; Chronic Disease; Circadian Clocks; Circadian Rhythm Signaling Peptides and Proteins; Clarithromycin; Coccidioides; Coccidioidomycosis; Cognitive Behavioral Therapy; Coinfection; Color; Coloring Agents; Computer Simulation; Computers, Molecular; Consensus; Corticosterone; Cyclic AMP Response Element-Binding Protein; Cytochrome P-450 Enzyme System; Death, Sudden, Cardiac; Density Functional Theory; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dialysis Solutions; Disease Models, Animal; Dogs; Dopamine Agonists; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Electrocardiography; Electrocardiography, Ambulatory; Electrolytes; Endocardium; Endocrine Disruptors; Endocytosis; Endoscopy, Gastrointestinal; Escherichia coli Proteins; Esters; Evolution, Molecular; Executive Function; Feasibility Studies; Female; Ferric Compounds; Fluorescence; Fluorescent Dyes; Fluorine Radioisotopes; Frailty; Free Radical Scavengers; Gabapentin; Geriatric Assessment; Glucaric Acid; Glucocorticoids; Glucose; Glucose Metabolism Disorders; Halogenated Diphenyl Ethers; Heart Rate; Heart Ventricles; HEK293 Cells; Helicobacter Infections; Helicobacter pylori; Hep G2 Cells; Hepatocytes; Humans; Hungary; Hydrogen Sulfide; Hydrogen-Ion Concentration; Immunologic Factors; Immunomodulation; Immunosuppressive Agents; Independent Living; Indocyanine Green; Infant; Infant Formula; Infant Mortality; Infant, Newborn; Infant, Newborn, Diseases; Inflorescence; Insulin Resistance; Insulins; International Agencies; Iron; Isotonic Solutions; Kidney Failure, Chronic; Kinetics; Lactones; Leukocytes, Mononuclear; Liver Neoplasms; Macular Edema; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetosomes; Male; Medical Audit; Mesenchymal Stem Cells; Metabolic Syndrome; Metformin; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Middle Aged; Molecular Conformation; Molecular Targeted Therapy; Motor Activity; Multiple Sclerosis; Mycophenolic Acid; Netherlands; Neuropsychological Tests; Nuclear Energy; Organs at Risk; Osteoarthritis; Osteoarthritis, Hip; Oxidation-Reduction; Palladium; Pericardium; Perinatal Death; Peritoneal Dialysis; Phantoms, Imaging; Pharmaceutical Preparations; Phospholipids; Phosphorylation; Physical Conditioning, Human; Physical Endurance; Pilot Projects; Polyketides; Polymers; Positron-Emission Tomography; Postoperative Period; Potassium; Powders; Pramipexole; Predictive Value of Tests; Pregabalin; Pregnancy; Pregnancy Outcome; Protein Structure, Secondary; Proton Pump Inhibitors; Puberty; Pulmonary Circulation; Quality Assurance, Health Care; Quantum Dots; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Rats, Sprague-Dawley; Receptors, CCR2; Receptors, Transferrin; Regeneration; Registries; Renal Insufficiency, Chronic; Reproducibility of Results; Research Design; Restless Legs Syndrome; Retina; Retinoid X Receptor alpha; Retrospective Studies; Rhenium; Risk Factors; RNA, Messenger; Severity of Illness Index; Sex Factors; Sodium; Sodium Fluoride; Solvents; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Stereoisomerism; Stroke; Structure-Activity Relationship; Tachycardia, Ventricular; Tetracycline; Tetrahydrofolate Dehydrogenase; Tetrahydronaphthalenes; Thermodynamics; Thiophenes; Time Factors; Tinidazole; Tomography, Optical Coherence; Tomography, X-Ray Computed; Topiramate; Toxoplasma; Toxoplasmosis, Cerebral; Transferrin; Treatment Outcome; Up-Regulation; Upper Extremity; Uremia; Uveitis; Vascular Remodeling; Ventricular Fibrillation; Ventricular Function, Left; Ventricular Function, Right; Ventricular Remodeling; Verapamil; Veterans; Visual Acuity; Vitrectomy; Water Pollutants, Chemical; Zea mays; Zirconium

2019
Novel synaptic plasticity enhancer drug to augment functional recovery with rehabilitation.
    Current opinion in neurology, 2019, Volume: 32, Issue:6

    Topics: Animals; Brain Injuries; Combined Modality Therapy; Exercise Therapy; Humans; Intercellular Signaling Peptides and Proteins; Maleates; Nerve Tissue Proteins; Neurological Rehabilitation; Neuronal Plasticity; Neuroprotective Agents; Recovery of Function; Stroke; Thiophenes

2019
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus

2016
Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications.
    Expert review of cardiovascular therapy, 2013, Volume: 11, Issue:2

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Humans; Ischemic Attack, Transient; Medication Adherence; Morpholines; Renal Insufficiency; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thromboembolism; Vitamin K; Warfarin

2013
Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
    Hospital practice (1995), 2013, Volume: 41, Issue:1

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Approval; Europe; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Venous Thromboembolism; Warfarin

2013
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
    Hospital practice (1995), 2013, Volume: 41, Issue:1

    Topics: Age Factors; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Comorbidity; Dabigatran; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyridines; Risk Factors; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin

2013
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Hospital practice (1995), 2013, Volume: 41, Issue:1

    Topics: Administration, Oral; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin

2013
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
    Hospital practice (1995), 2013, Volume: 41, Issue:1

    Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin

2013
[The role of internal medicine in preventing stroke in atrial fibrillation].
    Medicina clinica, 2012, Volume: 139 Suppl 2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Humans; Internal Medicine; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes

2012
[Advances in the secondary prevention of cardioembolic stroke].
    Medicina clinica, 2012, Volume: 139 Suppl 2

    Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Endovascular Procedures; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Spain; Stroke; Thiophenes

2012
[The new oral anticoagulants in special populations].
    Medicina clinica, 2012, Volume: 139 Suppl 2

    Topics: Administration, Oral; Age Factors; Anticoagulants; Benzimidazoles; Contraindications; Dabigatran; Embolism; Humans; Morpholines; Obesity; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thrombosis

2012
[Improvements in oral anticoagulant therapy for atrial fibrillation].
    Medicina clinica, 2013, Dec-07, Volume: 141, Issue:11

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Warfarin

2013
Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.
    International journal of clinical practice, 2013, Volume: 67, Issue:7

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Primary Health Care; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Workload

2013
[Factor Xa inhibitor (rivaroxaban and drugs under investigation)].
    Nihon rinsho. Japanese journal of clinical medicine, 2013, Volume: 71, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thromboembolism

2013
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
    Contributions to nephrology, 2013, Volume: 179

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Disease Management; Embolism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Intracranial Embolism; Male; Morpholines; Patient Selection; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Warfarin

2013
Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Drugs, 2013, Volume: 73, Issue:7

    Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Drug Interactions; Embolism; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes

2013
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies.
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:2

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Endoscopy; Gastrointestinal Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin

2013
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
    Stroke, 2013, Volume: 44, Issue:6 Suppl 1

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Humans; Monitoring, Physiologic; Morpholines; Prodrugs; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Vitamin K; Warfarin

2013
Novel oral anticoagulants in gastroenterology practice.
    Gastrointestinal endoscopy, 2013, Volume: 78, Issue:2

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Gastrointestinal Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes

2013
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
    Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:24

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Electric Countershock; Enoxaparin; Heparin; Humans; International Normalized Ratio; Morpholines; Phenprocoumon; Practice Guidelines as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin

2013
Stroke prevention in patients with atrial fibrillation: focus on new oral anticoagulants.
    Postgraduate medicine, 2013, Volume: 125, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes

2013
Pharmacokinetic considerations for antithrombotic therapies in stroke.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:10

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Tetrazoles; Thiophenes; Thrombin; Ticlopidine; Vitamin K

2013
Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    The Canadian journal of cardiology, 2013, Volume: 29, Issue:7 Suppl

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Humans; Morpholines; Outcome Assessment, Health Care; Patient Selection; Polymorphism, Genetic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin

2013
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2013, Volume: 16, Issue:4

    Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cost-Benefit Analysis; Dabigatran; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Time Factors; Warfarin

2013
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.
    Heart failure reviews, 2014, Volume: 19, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chronic Disease; Dabigatran; Drug Monitoring; Heart Failure; Hemorrhage; Humans; Morpholines; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Warfarin

2014
Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
    Postgraduate medicine, 2013, Volume: 125, Issue:2

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin

2013
New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.
    Reviews on recent clinical trials, 2013, Volume: 8, Issue:2

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Morpholines; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin

2013
What are the new therapeutic alternatives to warfarin in atrial fibrillation?
    JPMA. The Journal of the Pakistan Medical Association, 2013, Volume: 63, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pakistan; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin

2013
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Clinical therapeutics, 2013, Volume: 35, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin

2013
New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
    Neurologic clinics, 2013, Volume: 31, Issue:3

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes

2013
Novel oral anticoagulants: a review of new agents.
    Postgraduate medicine, 2013, Volume: 125, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Postoperative Complications; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis

2013
Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban.
    British journal of haematology, 2013, Volume: 163, Issue:2

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes

2013
Novel oral anticoagulants in non-valvular atrial fibrillation.
    Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism

2013
Novel oral anticoagulants in secondary prevention of stroke.
    Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Guidelines as Topic; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin

2013
New oral anticoagulants in elderly patients.
    Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin

2013
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
    Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin

2013
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
    The Canadian journal of cardiology, 2013, Volume: 29, Issue:11

    Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine

2013
Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.
    Clinical pharmacology and therapeutics, 2014, Volume: 95, Issue:2

    Topics: Algorithms; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Dosage Calculations; Humans; Morpholines; Pharmacogenetics; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin

2014
Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
    Polskie Archiwum Medycyny Wewnetrznej, 2013, Volume: 123, Issue:11

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Fibrinolytic Agents; Forecasting; Humans; Morpholines; Percutaneous Coronary Intervention; Postoperative Care; Postoperative Hemorrhage; Premedication; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin

2013
[Prevention of stroke in patients with atrial fibrillation: a role of modern anticoagulants].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2013, Volume: 113, Issue:9 Pt 2

    Topics: Anticoagulants; Atrial Fibrillation; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin

2013
Novel oral anticoagulants: a focused review for stroke physicians.
    International journal of stroke : official journal of the International Stroke Society, 2014, Volume: 9, Issue:1

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Child; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes

2014
Outpatient management of oral anticoagulation in atrial fibrillation.
    Critical care nursing clinics of North America, 2013, Volume: 25, Issue:4

    Topics: Ambulatory Care; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin

2013
[Evidence of novel oral anticoagulants (NOAC)].
    Rinsho shinkeigaku = Clinical neurology, 2013, Volume: 53, Issue:11

    Topics: Administration, Ophthalmic; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Infarction; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin

2013
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis.
    Stroke, 2014, Volume: 45, Issue:2

    Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studies; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Population; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Secondary Prevention; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Vascular Diseases

2014
Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Journal of clinical pharmacy and therapeutics, 2014, Volume: 39, Issue:2

    Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes

2014
{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
    Drug and therapeutics bulletin, 2014, Volume: 52, Issue:1

    Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes

2014
[New anticoagulants in patients with atrial fibrillation].
    MMW Fortschritte der Medizin, 2013, May-02, Volume: 155, Issue:8

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Infarction; Dabigatran; Humans; Intracranial Embolism; Ischemic Attack, Transient; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K

2013
New oral anticoagulants in practice: pharmacological and practical considerations.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:3

    Topics: Administration, Oral; Aging; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Complementary Therapies; Dabigatran; Drug Interactions; Drug Monitoring; Humans; International Normalized Ratio; Kidney Diseases; Liver Diseases; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin

2014
New oral anticoagulant agents - general features and outcomes in subsets of patients.
    Thrombosis and haemostasis, 2014, Apr-01, Volume: 111, Issue:4

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin

2014
[General characteristics of the new oral anticoagulants].
    Geriatrie et psychologie neuropsychiatrie du vieillissement, 2013, Volume: 11, Issue:1 Suppl

    Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drugs, Investigational; Humans; Iatrogenic Disease; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K

2013
[Novel oral anticoagulants and atrial fibrillation in the elderly].
    Geriatrie et psychologie neuropsychiatrie du vieillissement, 2013, Volume: 11, Issue:1 Suppl

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Drugs, Investigational; Half-Life; Humans; Intracranial Embolism; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Vitamin K

2013
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.
    The American journal of cardiology, 2014, Mar-01, Volume: 113, Issue:5

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Ticlopidine

2014
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
    Atherosclerosis, 2014, Volume: 233, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine

2014
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions.
    Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Data Interpretation, Statistical; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome

2014
Practical aspects of new oral anticoagulant use in atrial fibrillation.
    Polskie Archiwum Medycyny Wewnetrznej, 2014, Volume: 124, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin

2014
Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.
    Vascular health and risk management, 2014, Volume: 10

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Drug Administration Schedule; Drug Interactions; Drug Substitution; Hemorrhage; Humans; Morpholines; Patient Selection; Perioperative Care; Practice Guidelines as Topic; Preventive Health Services; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome

2014
[Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
    Journal des maladies vasculaires, 2014, Volume: 39, Issue:3

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzamides; Blood Coagulation; Embolism; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia; Thrombosis

2014
The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Journal of cardiovascular pharmacology and therapeutics, 2014, Volume: 19, Issue:6

    Topics: Acute Coronary Syndrome; Administration, Oral; Atrial Fibrillation; Blood Coagulation; Cost-Benefit Analysis; Drug Costs; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome

2014
The newer direct oral anticoagulants: a practical guide.
    Clinical medicine (London, England), 2014, Volume: 14, Issue:2

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin

2014
Anticoagulation in atrial fibrillation.
    BMJ (Clinical research ed.), 2014, Apr-14, Volume: 348

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin

2014
Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
    Current vascular pharmacology, 2014, Volume: 12, Issue:3

    Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Primary Prevention; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes

2014
Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2014, Volume: 40, Issue:3

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Translational Research, Biomedical; Treatment Outcome

2014
Newer clinically available antithrombotics and their antidotes.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2014, Volume: 40, Issue:3

    Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism

2014
Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
    Expert review of cardiovascular therapy, 2014, Volume: 12, Issue:8

    Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin

2014
Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients.
    Mayo Clinic proceedings, 2014, Volume: 89, Issue:7

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism

2014
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials.
    The Canadian journal of cardiology, 2014, Volume: 30, Issue:8

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thromboembolism

2014
Atrial fibrillation - new frontiers in anticoagulation.
    Cardiovascular & hematological disorders drug targets, 2014, Volume: 14, Issue:1

    Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes

2014
Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
    Cardiovascular & hematological disorders drug targets, 2014, Volume: 14, Issue:1

    Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Discovery; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin

2014
Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications.
    Drugs, 2014, Volume: 74, Issue:14

    Topics: Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hip Joint; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism

2014
Oral anticoagulants for stroke prevention in atrial fibrillation.
    Current problems in cardiology, 2014, Volume: 39, Issue:9

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Drug Therapy, Combination; Humans; Morpholines; Patient Preference; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes

2014
Target-specific oral anticoagulants: practice issues for the clinician.
    Hospital practice (1995), 2014, Volume: 42, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin

2014
Switching between oral anticoagulants.
    Hospital practice (1995), 2014, Volume: 42, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; United States; Warfarin

2014
Update on secondary prevention of ischaemic stroke.
    JPMA. The Journal of the Pakistan Medical Association, 2014, Volume: 64, Issue:7

    Topics: Anticoagulants; Blood Coagulation; Brain Ischemia; Foramen Ovale, Patent; Humans; Intracranial Embolism; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Ventricular Dysfunction, Left

2014
Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
    International journal of clinical pharmacology and therapeutics, 2015, Volume: 53, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Patient Safety; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism

2015
[Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
    Orvosi hetilap, 2014, Oct-19, Volume: 155, Issue:42

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Vitamin K; Warfarin

2014
Balancing ischaemia and bleeding risks with novel oral anticoagulants.
    Nature reviews. Cardiology, 2014, Volume: 11, Issue:12

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism

2014
Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
    Canadian family physician Medecin de famille canadien, 2014, Volume: 60, Issue:11

    Topics: Acute Disease; Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin

2014
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
    Annual review of medicine, 2015, Volume: 66

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin

2015
Overview of the new oral anticoagulants: opportunities and challenges.
    Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:5

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sensitivity and Specificity; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin

2015
Brave new world: the current and future use of novel anticoagulants.
    Thrombosis research, 2008, Volume: 123 Suppl 1

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism

2008
Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.
    European journal of haematology, 2009, Volume: 82, Issue:5

    Topics: Anticoagulants; Antithrombin III; Clinical Trials as Topic; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism

2009
New findings with old drugs for osteoporosis.
    Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:3

    Topics: Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Female; Humans; Norpregnenes; Organometallic Compounds; Osteoporosis, Postmenopausal; Stroke; Thiophenes

2009
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
    Current opinion in cardiology, 2010, Volume: 25, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzamides; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin

2010
[New oral anticoagulants: better than vitamin K antagonists?].
    Der Internist, 2010, Volume: 51, Issue:12

    Topics: Anticoagulants; Antithrombin Proteins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis; Vitamin K

2010
[Novel anticoagulants for stroke prevention in atrial fibrillation].
    Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:46

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism

2010
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
    Annual review of medicine, 2011, Volume: 62

    Topics: Acute Coronary Syndrome; Amidines; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Treatment Outcome; Vitamin K

2011
Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.
    Expert opinion on investigational drugs, 2011, Volume: 20, Issue:4

    Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Drugs, Investigational; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Venous Thromboembolism

2011
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.
    European heart journal, 2011, Volume: 32, Issue:16

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Approval; Factor X; Humans; Morpholines; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism

2011
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).
    Current atherosclerosis reports, 2011, Volume: 13, Issue:4

    Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Fibrinolytic Agents; Foramen Ovale, Patent; Genotype; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine

2011
[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Medecine sciences : M/S, 2011, Volume: 27, Issue:5

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Approval; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Forecasting; France; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Thrombophilia; Venous Thromboembolism

2011
Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview.
    Vascular health and risk management, 2011, Volume: 7

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus; Drug Resistance; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Thrombosis; Time Factors; Treatment Outcome

2011
[Atrial fibrillation: what the GP needs to know].
    MMW Fortschritte der Medizin, 2011, Sep-22, Volume: 153, Issue:38

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; General Practice; Humans; International Normalized Ratio; Medication Adherence; Morpholines; Partial Thromboplastin Time; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes

2011
A new era of antithrombotic therapy in patients with atrial fibrillation.
    The American journal of the medical sciences, 2012, Volume: 344, Issue:2

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin

2012
[Current status and future of anti-Xa inhibitors].
    Rinsho shinkeigaku = Clinical neurology, 2011, Volume: 51, Issue:11

    Topics: Anticoagulants; Atrial Fibrillation; Azepines; Benzamides; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes

2011
Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
    Expert review of neurotherapeutics, 2012, Volume: 12, Issue:2

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes

2012
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
    Cardiology journal, 2012, Volume: 19, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin

2012
A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long‑term prevention of thromboembolic complications in patients with atrial fibrillation?
    Polskie Archiwum Medycyny Wewnetrznej, 2012, Volume: 122, Issue:1-2

    Topics: Anticoagulants; Atrial Fibrillation; Drugs, Investigational; Factor X; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Vitamin K; Warfarin

2012
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
    Journal of internal medicine, 2012, Volume: 271, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drugs, Investigational; Heparin; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K

2012
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
    The American journal of cardiology, 2012, Aug-01, Volume: 110, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin

2012
Novel oral anticoagulants--key messages for the angiologist.
    VASA. Zeitschrift fur Gefasskrankheiten, 2012, Volume: 41, Issue:3

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Predictive Value of Tests; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism

2012
Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.
    Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:7

    Topics: Acute Coronary Syndrome; Administration, Oral; Blood Coagulation Tests; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Drug Interactions; Factor Xa; Factor Xa Inhibitors; Half-Life; Humans; Morpholines; Myocardial Infarction; Pulmonary Embolism; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thrombosis

2012
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
    Critical pathways in cardiology, 2012, Volume: 11, Issue:2

    Topics: Anticoagulants; Antithrombin Proteins; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; Chemoprevention; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin

2012
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2012, Volume: 35, Issue:1

    Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin

2012
[Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?].
    MMW Fortschritte der Medizin, 2012, Mar-22, Volume: 154, Issue:5

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Factor Xa Inhibitors; Guideline Adherence; Hemorrhage; Humans; Intracranial Embolism; Morpholines; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes

2012
[Clinical management of the new anticoagulants].
    Neurologia (Barcelona, Spain), 2012, Volume: 27 Suppl 1

    Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Drugs, Investigational; Hemorrhage; Humans; Morpholines; Multicenter Studies as Topic; Patient Care Planning; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombophilia; Vitamin K

2012
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Advances in therapy, 2012, Volume: 29, Issue:6

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin

2012
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:3

    Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Heart Valve Diseases; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Vitamin K; Warfarin

2012
Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.
    QJM : monthly journal of the Association of Physicians, 2012, Volume: 105, Issue:10

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Comparative Effectiveness Research; Dabigatran; Drug Monitoring; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Outcome and Process Assessment, Health Care; Pharmacovigilance; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin

2012
New oral anticoagulants in the ED setting: a review.
    The American journal of emergency medicine, 2012, Volume: 30, Issue:9

    Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Emergency Service, Hospital; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism

2012
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    International angiology : a journal of the International Union of Angiology, 2012, Volume: 31, Issue:4

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Chi-Square Distribution; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Odds Ratio; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome

2012
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:10

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Preventive Health Services; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin

2012
[New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients].
    Zeitschrift fur Gerontologie und Geriatrie, 2012, Volume: 45, Issue:6

    Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Female; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes

2012
Clinical considerations of anticoagulation therapy for patients with atrial fibrillation.
    Journal of Zhejiang University. Science. B, 2012, Volume: 13, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiology; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin

2012
Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
    Minerva cardioangiologica, 2012, Volume: 60, Issue:4

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin

2012
Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome.
    Future cardiology, 2012, Volume: 8, Issue:4

    Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Drug Approval; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin

2012
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
    Canadian family physician Medecin de famille canadien, 2012, Volume: 58, Issue:8

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Health Status Indicators; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin

2012
Stroke prevention in atrial fibrillation: concepts and controversies.
    Current cardiology reviews, 2012, Volume: 8, Issue:4

    Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Dronedarone; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin

2012
[The new anticoagulants - their role in secondary prevention of thromboembolism after stroke].
    Therapeutische Umschau. Revue therapeutique, 2012, Volume: 69, Issue:9

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Vitamin K

2012
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:4

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Ischemic Attack, Transient; Medical Records; Morpholines; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism

2012
New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Oct-01, Volume: 12, Issue:5

    Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin

2012
[New oral anticoagulants for atrial fibrillation: a neurologist's view].
    Nederlands tijdschrift voor geneeskunde, 2012, Volume: 156, Issue:39

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes

2012
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:5

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pregnancy; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin

2012
What did we learn from new oral anticoagulant treatment?
    Thrombosis research, 2012, Volume: 130 Suppl 1

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Half-Life; Hemorrhage; Humans; Metabolic Clearance Rate; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis

2012
Antithrombotic treatment of atrial fibrillation: new insights.
    Thrombosis research, 2012, Volume: 130 Suppl 1

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K

2012
Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial.
    Expert review of cardiovascular therapy, 2012, Volume: 10, Issue:8

    Topics: Anticoagulants; Atrial Fibrillation; Gastrointestinal Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin

2012
Anticoagulant treatment: the end of the old agents?
    Swiss medical weekly, 2012, Volume: 142

    Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Prothrombin; Rivaroxaban; Stroke; Thiophenes; Thromboembolism

2012
[New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
    Kardiologia polska, 2012, Volume: 70, Issue:10

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Humans; Kidney Failure, Chronic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin

2012
[Stroke risk--atrial fibrillation].
    MMW Fortschritte der Medizin, 2012, Nov-01, Volume: 154, Issue:19

    Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Sectional Studies; Dabigatran; Humans; International Normalized Ratio; Minimally Invasive Surgical Procedures; Morpholines; Population Dynamics; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes

2012
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Thrombosis and haemostasis, 2013, Volume: 109, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2013
The novel anticoagulants: the surgeons' prospective.
    Surgery, 2013, Volume: 153, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surgical Procedures, Operative; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin

2013
New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures.
    Internal and emergency medicine, 2013, Volume: 8, Issue:2

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis

2013
[Rivaroxaban in prevention of stroke in patients with atrial fibrillation].
    Ideggyogyaszati szemle, 2012, Nov-30, Volume: 65, Issue:11-12

    Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Drug Administration Schedule; Humans; International Normalized Ratio; Morpholines; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome

2012
Implications of new anticoagulants in primary practice.
    International journal of clinical practice, 2013, Volume: 67, Issue:2

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism

2013
A review of oral anticoagulants in patients with atrial fibrillation.
    Postgraduate medicine, 2012, Volume: 124, Issue:6

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin

2012
Rivaroxaban: an oral factor Xa inhibitor.
    Clinical therapeutics, 2013, Volume: 35, Issue:1

    Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism

2013
[Anticoagulant therapy in stroke patients].
    Ugeskrift for laeger, 2013, Jan-28, Volume: 175, Issue:5

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Radiography; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Vitamin K

2013
Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
    The Journal of emergency medicine, 2013, Volume: 45, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emergencies; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; United States; United States Food and Drug Administration; Warfarin

2013
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
    Postgraduate medicine, 2013, Volume: 125, Issue:1

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes

2013
Effects of eprosartan on target organ protection.
    Vascular health and risk management, 2006, Volume: 2, Issue:1

    Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Endothelium, Vascular; Humans; Hypertension; Imidazoles; Neuroprotective Agents; Nitrendipine; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Research Design; Risk Factors; Stroke; Thiophenes; Treatment Outcome

2006
Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
    Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:6

    Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Determination; Cardiovascular Diseases; Cognition Disorders; Female; Humans; Hypertension; Imidazoles; Male; Sensitivity and Specificity; Severity of Illness Index; Stroke; Survival Analysis; Systole; Thiophenes; Treatment Outcome

2007
Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
    Current medical research and opinion, 2007, Volume: 23 Suppl 5

    Topics: Acrylates; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Animals; Cognition Disorders; Dementia, Vascular; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Neuropsychological Tests; Rats; Stroke; Thiophenes

2007
Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
    Current medical research and opinion, 2007, Volume: 23 Suppl 5

    Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Catecholamines; Humans; Hypertension; Imidazoles; Norepinephrine; Stroke; Tetrazoles; Thiophenes; Valine; Valsartan

2007
Rivaroxaban, an oral direct factor Xa inhibitor.
    Expert opinion on investigational drugs, 2008, Volume: 17, Issue:6

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Animals; Anticoagulants; Atrial Fibrillation; Binding Sites; Clinical Trials as Topic; Comorbidity; Drug Evaluation, Preclinical; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Rats; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Warfarin

2008

Trials

61 trial(s) available for thiophenes and Stroke

ArticleYear
[Rivaroxaban in prevention of stroke in elderly patients with non-valvular atrial fibrillation].
    Kardiologiia, 2019, Nov-17, Volume: 59, Issue:12S

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome

2019
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus

2016
Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.
    Diabetes care, 2018, Volume: 41, Issue:8

    Topics: Acute Coronary Syndrome; Adiponectin; Aged; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Nonesterified; Female; Humans; Male; Middle Aged; Myocardial Infarction; Oxazoles; Retrospective Studies; Stroke; Thiophenes; Treatment Outcome

2018
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
    Journal of the American College of Cardiology, 2013, May-14, Volume: 61, Issue:19

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Electric Countershock; Female; Humans; Male; Middle Aged; Morpholines; Multicenter Studies as Topic; Multivariate Analysis; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin

2013
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
    Journal of the American Heart Association, 2013, Feb-19, Volume: 2, Issue:1

    Topics: Aged; Anticoagulants; Asia; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Drug Monitoring; Europe; Female; Healthcare Disparities; Humans; International Normalized Ratio; Linear Models; Male; Morpholines; Multivariate Analysis; North America; Predictive Value of Tests; Residence Characteristics; Rivaroxaban; South Africa; South America; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin

2013
Prophylactic effects of duloxetine on post-stroke depression symptoms: an open single-blind trial.
    European neurology, 2013, Volume: 69, Issue:6

    Topics: Aged; Antidepressive Agents; Depression; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Single-Blind Method; Stroke; Thiophenes

2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
    Circulation. Cardiovascular quality and outcomes, 2013, Volume: 6, Issue:4

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Clinical Protocols; Continuity of Patient Care; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Embolism; Factor Xa; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; Proportional Hazards Models; Research Design; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Vitamin K; Warfarin

2013
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
    Annals of internal medicine, 2013, Jun-18, Volume: 158, Issue:12

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin

2013
Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial.
    Journal of thrombosis and thrombolysis, 2014, Volume: 37, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Antibodies, Antiphospholipid; Factor Xa Inhibitors; Female; Humans; Immunoglobulin M; Male; Middle Aged; Morpholines; Myocardial Infarction; Phosphorylcholine; Rivaroxaban; Stroke; Thiophenes

2014
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Clinical therapeutics, 2013, Volume: 35, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin

2013
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation.
    Vascular, 2014, Volume: 22, Issue:4

    Topics: Administration, Oral; Aged; Anticoagulants; Asian People; Atrial Fibrillation; China; Double-Blind Method; Embolism; Female; Hemorrhage; Humans; Male; Morpholines; Primary Prevention; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin

2014
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
    Lancet (London, England), 2013, Aug-17, Volume: 382, Issue:9892

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Thiophenes; Ticlopidine; Treatment Outcome

2013
Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:2

    Topics: Aged; Anticoagulants; Asian People; Atrial Fibrillation; Disease-Free Survival; Double-Blind Method; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Morpholines; Prospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin

2014
Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.
    American heart journal, 2013, Volume: 166, Issue:3

    Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Morbidity; Myocardial Infarction; Oxazoles; Peroxisome Proliferator-Activated Receptors; Risk Factors; Stroke; Thiophenes; Treatment Outcome

2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
    European heart journal, 2014, Volume: 35, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Female; Humans; Kaplan-Meier Estimate; Male; Morpholines; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin

2014
Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarctio
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:12

    Topics: Acute Coronary Syndrome; Aged; Calcium Channel Blockers; Clopidogrel; Double-Blind Method; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Proton Pump Inhibitors; Risk Factors; Stroke; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome

2013
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF.
    European heart journal, 2014, Volume: 35, Issue:4

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Humans; Male; Morpholines; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin

2014
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).
    Journal of the American College of Cardiology, 2014, Mar-11, Volume: 63, Issue:9

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Pressure; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Vitamin K; Warfarin

2014
Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REA
    Journal of cardiovascular translational research, 2014, Volume: 7, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Clinical Protocols; Coronary Thrombosis; Drug Administration Schedule; Fibrinolytic Agents; Germany; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Stents; Stroke; Thiophenes; Ticagrelor; Time Factors; Time-to-Treatment; Treatment Outcome

2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stro
    Circulation, 2014, May-06, Volume: 129, Issue:18

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Intracranial Embolism; Male; Morpholines; Proportional Hazards Models; Prospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin

2014
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.
    European heart journal, 2014, Jul-21, Volume: 35, Issue:28

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Atrial Fibrillation; Blood Transfusion; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Hospitalization; Humans; Male; Morpholines; Plasma; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin

2014
Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
    JAMA, 2014, Apr-16, Volume: 311, Issue:15

    Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Myocardial Infarction; Oxazoles; Peroxisome Proliferator-Activated Receptors; Risk; Stroke; Survival Analysis; Thiophenes; Treatment Outcome

2014
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in at
    Stroke, 2014, Volume: 45, Issue:5

    Topics: Aged; Anticoagulants; Asian People; Atrial Fibrillation; Black People; Double-Blind Method; Embolism; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Morpholines; Prospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin

2014
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.
    Journal of the American Heart Association, 2014, Apr-22, Volume: 3, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Drug Monitoring; Embolism; Europe; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; North America; Point-of-Care Systems; Predictive Value of Tests; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin

2014
Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial.
    Stroke, 2014, Volume: 45, Issue:6

    Topics: Aged; Anticoagulants; Asia, Eastern; Asian People; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin

2014
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism
    Circulation, 2014, Jul-08, Volume: 130, Issue:2

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin

2014
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
    Current medical research and opinion, 2014, Volume: 30, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Stents; Stroke; Thiophenes; Ticlopidine

2014
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.
    Vascular health and risk management, 2014, Volume: 10

    Topics: Africa; Atrial Fibrillation; Clinical Protocols; Europe; Factor Xa Inhibitors; Humans; Latin America; Middle East; Morpholines; Prospective Studies; Research Design; Risk Assessment; Risk Factors; Rivaroxaban; Sample Size; Stroke; Thiophenes; Time Factors; Treatment Outcome

2014
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial.
    European heart journal, 2014, Dec-14, Volume: 35, Issue:47

    Topics: Aged; Anticoagulants; Aortic Valve Insufficiency; Atrial Fibrillation; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Mitral Valve Insufficiency; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin

2014
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.
    European heart journal, 2014, Dec-14, Volume: 35, Issue:47

    Topics: Administration, Oral; Aged; Atrial Fibrillation; Electric Countershock; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K

2014
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.
    European heart journal, 2015, Feb-01, Volume: 36, Issue:5

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cause of Death; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Morpholines; Prospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin

2015
Rationale and design of Triple AXEL: trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:1

    Topics: Adult; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Research Design; Rivaroxaban; Stroke; Thiophenes

2015
Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban.
    Annals of hematology, 2015, Volume: 94, Issue:9

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa; Factor Xa Inhibitors; Female; Heparin; Humans; Male; Morpholines; Prothrombin Time; Rivaroxaban; Stroke; Thiophenes

2015
Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
    American heart journal, 2015, Volume: 170, Issue:1

    Topics: Aged; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Early Termination of Clinical Trials; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Myalgia; Myocardial Infarction; Myositis; Oxazoles; Peripheral Arterial Disease; PPAR alpha; PPAR gamma; Prediabetic State; Stroke; Thiophenes; Treatment Outcome

2015
Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger.
    Cerebrovascular diseases (Basel, Switzerland), 2008, Volume: 26, Issue:1

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Hemorrhage; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Secondary Prevention; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome

2008
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.
    European heart journal, 2008, Volume: 29, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Stroke; Thiophenes; Ticlopidine; Treatment Outcome

2008
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
    Lancet (London, England), 2009, Jul-04, Volume: 374, Issue:9683

    Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Chest Pain; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Myocardial Infarction; Proportional Hazards Models; Pyridines; Recurrence; Risk Reduction Behavior; Rivaroxaban; Safety; Statistics, Nonparametric; Stroke; Thiophenes; Treatment Outcome

2009
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla
    Journal of the American College of Cardiology, 2009, Aug-18, Volume: 54, Issue:8

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Stroke; Thiophenes; Ticlopidine

2009
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
    American heart journal, 2010, Volume: 159, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Drug Administration Schedule; Embolism; Factor Xa Inhibitors; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Humans; Medical Records; Morpholines; Research Design; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Vitamin K; Warfarin

2010
Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial.
    Pain, 2011, Volume: 152, Issue:2

    Topics: Adult; Disability Evaluation; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Hyperalgesia; Male; Middle Aged; Neuralgia; Outcome Assessment, Health Care; Pain Measurement; Pain Threshold; Placebo Effect; Spinal Cord Injuries; Stroke; Thiophenes; Treatment Outcome

2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
    The New England journal of medicine, 2011, Sep-08, Volume: 365, Issue:10

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Hemorrhage; Humans; Intention to Treat Analysis; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin

2011
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
    European heart journal, 2011, Volume: 32, Issue:19

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Hemorrhage; Humans; Male; Morpholines; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin

2011
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
    Clinical pharmacokinetics, 2011, Volume: 50, Issue:10

    Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Body Weight; Computer Simulation; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Models, Biological; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis; Young Adult

2011
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.
    The Lancet. Neurology, 2012, Volume: 11, Issue:4

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Humans; Intention to Treat Analysis; Ischemic Attack, Transient; Morpholines; Multicenter Studies as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Treatment Outcome; Warfarin

2012
Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –.
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Morpholines; Prospective Studies; Rivaroxaban; Stroke; Thiophenes; Warfarin

2012
The effects of the dopamine agonist rotigotine on hemispatial neglect following stroke.
    Brain : a journal of neurology, 2012, Volume: 135, Issue:Pt 8

    Topics: Adult; Aged; Aged, 80 and over; Dopamine Agonists; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Perceptual Disorders; Psychomotor Performance; Stroke; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome; Young Adult

2012
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
    The New England journal of medicine, 2012, Oct-04, Volume: 367, Issue:14

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Ticlopidine

2012
Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue.
    The Journal of neuropsychiatry and clinical neurosciences, 2012,Summer, Volume: 24, Issue:3

    Topics: Activities of Daily Living; Adult; Aged; Antidepressive Agents; Anxiety; Citalopram; Depression; Duloxetine Hydrochloride; Fatigue; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Sertraline; Stroke; Thiophenes; Time Factors; Treatment Outcome; Young Adult

2012
Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:6

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Biomarkers; Blood Proteins; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Proteomics; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Warfarin

2012
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
    JAMA, 2012, Nov-07, Volume: 308, Issue:17

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Stroke; Thiophenes; Ticlopidine; Treatment Outcome

2012
Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel.
    Circulation. Cardiovascular quality and outcomes, 2013, Jan-01, Volume: 6, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Models, Statistical; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticlopidine; Treatment Outcome

2013
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K ant
    Circulation, 2013, Jan-15, Volume: 127, Issue:2

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa; Female; Follow-Up Studies; Humans; Incidence; Male; Morpholines; Predictive Value of Tests; Reproducibility of Results; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin

2013
Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment.
    Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Japan; Kidney; Male; Middle Aged; Morpholines; Renal Insufficiency; Reproducibility of Results; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin

2013
Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:8

    Topics: Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Morpholines; Prospective Studies; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Treatment Outcome; Warfarin

2013
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention o
    Journal of the American College of Cardiology, 2013, Feb-12, Volume: 61, Issue:6

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Morpholines; Outcome Assessment, Health Care; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Time Factors; Warfarin; Withholding Treatment

2013
[Antihypertensive treatment with eprosartan mesilate of patients in acute and late periods of ischemic stroke].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2003, Volume: 103, Issue:11

    Topics: Acrylates; Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Chi-Square Distribution; Data Interpretation, Statistical; Diastole; Female; Hemodynamics; Humans; Hypertension; Imidazoles; Male; Middle Aged; Quality of Life; Recurrence; Stroke; Systole; Thiophenes; Time Factors

2003
Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
    Stroke, 2005, Volume: 36, Issue:6

    Topics: Acrylates; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Body Mass Index; Calcium; Cardiovascular Diseases; Female; Humans; Hypertension; Imidazoles; Magnetic Resonance Spectroscopy; Male; Middle Aged; Nitrendipine; Prospective Studies; Recurrence; Risk Factors; Single-Blind Method; Sodium Chloride Symporter Inhibitors; Stroke; Thiophenes; Time Factors; Treatment Outcome

2005
Morbidity and mortality after stroke--eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES).
    Stroke, 2006, Volume: 37, Issue:2

    Topics: Acrylates; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Data Interpretation, Statistical; Diuretics; Humans; Imidazoles; Internal Medicine; Ischemic Attack, Transient; Morbidity; Neurology; Nitrendipine; Prospective Studies; Stroke; Thiophenes

2006
MOSES raises questions.
    Stroke, 2006, Volume: 37, Issue:2

    Topics: Acrylates; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Data Interpretation, Statistical; Humans; Imidazoles; Ischemic Attack, Transient; Nitrendipine; Research Design; Risk Factors; Stroke; Thiophenes

2006
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Thrombosis; Ticlopidine

2007
Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
    Current medical research and opinion, 2007, Volume: 23 Suppl 5

    Topics: Acrylates; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Animals; Cognition Disorders; Dementia, Vascular; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Neuropsychological Tests; Rats; Stroke; Thiophenes

2007

Other Studies

192 other study(ies) available for thiophenes and Stroke

ArticleYear
Stimulation of angiotensin II receptor 2 preserves cognitive function and is associated with an enhanced cerebral vascular density after stroke.
    Vascular pharmacology, 2021, Volume: 141

    Topics: Animals; Cognition; Female; Imidazoles; Male; Microvascular Density; Rats; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Stroke; Sulfonamides; Thiophenes

2021
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial.
    Journal of the American Heart Association, 2021, 10-05, Volume: 10, Issue:19

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Humans; Intention to Treat Analysis; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome

2021
Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation.
    Acta pharmacologica Sinica, 2022, Volume: 43, Issue:10

    Topics: Anticoagulants; Atrial Fibrillation; Bilirubin; China; Factor Xa Inhibitors; Humans; Morpholines; Nucleotides; Prospective Studies; Rivaroxaban; Stroke; Thiophenes

2022
Direct AT2R Stimulation Slows Post-stroke Cognitive Decline in the 5XFAD Alzheimer's Disease Mice.
    Molecular neurobiology, 2022, Volume: 59, Issue:7

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognitive Dysfunction; Disease Models, Animal; Humans; Imidazoles; Mice; Mice, Transgenic; Neurodegenerative Diseases; Receptor, Angiotensin, Type 2; Stroke; Sulfonamides; Thiophenes

2022
Contralesional angiotensin type 2 receptor activation contributes to recovery in experimental stroke.
    Neurochemistry international, 2022, Volume: 158

    Topics: Animals; Diabetes Mellitus, Experimental; Imidazoles; Infarction, Middle Cerebral Artery; Rats; Rats, Wistar; Receptor, Angiotensin, Type 2; Stroke; Sulfonamides; Thiophenes

2022
Delayed Administration of Angiotensin II Type 2 Receptor (AT2R) Agonist Compound 21 Prevents the Development of Post-stroke Cognitive Impairment in Diabetes Through the Modulation of Microglia Polarization.
    Translational stroke research, 2020, Volume: 11, Issue:4

    Topics: Animals; Cell Polarity; Cognitive Dysfunction; Diabetes Mellitus, Experimental; Diet, High-Fat; Imidazoles; Male; Microglia; Rats, Wistar; Receptor, Angiotensin, Type 2; Streptozocin; Stroke; Sulfonamides; Thiophenes

2020
Two Mixed-ligand Coordination Polymers: Crystal Structures and Protective Effect on Ischemic Stroke by Increasing glp1r Expression.
    Journal of oleo science, 2020, Volume: 69, Issue:7

    Topics: Animals; Brain; Chemical Phenomena; Cognition; Coordination Complexes; Crystallization; Endothelial Cells; Gene Expression; Glucagon-Like Peptide-1 Receptor; Imidazoles; Ligands; Maze Learning; Metals; Mice; Models, Molecular; Molecular Conformation; Polymers; Stroke; Structure-Activity Relationship; Thiophenes; X-Ray Diffraction

2020
A Stretchable and Transparent Electrode Based on PEGylated Silk Fibroin for In Vivo Dual-Modal Neural-Vascular Activity Probing.
    Advanced materials (Deerfield Beach, Fla.), 2021, Volume: 33, Issue:34

    Topics: Animals; Brain-Computer Interfaces; Disease Models, Animal; Elastic Modulus; Electric Conductivity; Electrodes; Electrodes, Implanted; Electronics; Electrophysiology; Epoxy Resins; Fibroins; Hydrogels; Polystyrenes; Pressure; Rats; Silk; Spectroscopy, Fourier Transform Infrared; Stress, Mechanical; Stroke; Thiophenes

2021
Present status and future orientation of rivaroxaban application in patients with nonvulvular atrial fibrillation.
    Thrombosis research, 2017, Volume: 156

    Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin

2017
Protective effects of the angiotensin II AT
    Clinical science (London, England : 1979), 2018, 03-15, Volume: 132, Issue:5

    Topics: Animals; Brain; Brain Ischemia; Cerebral Infarction; Drug Administration Routes; Drug Delivery Systems; Humans; Male; Nasal Mucosa; Neuroprotective Agents; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Stroke; Sulfonamides; Thiophenes

2018
Dose-response, therapeutic time-window and tPA-combinatorial efficacy of compound 21: A randomized, blinded preclinical trial in a rat model of thromboembolic stroke.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2019, Volume: 39, Issue:8

    Topics: Animals; Behavior, Animal; Disease Models, Animal; Fibrinolytic Agents; Male; Random Allocation; Rats; Rats, Wistar; Recovery of Function; Stroke; Sulfonamides; Thiophenes; Thromboembolism; Tissue Plasminogen Activator

2019
CRMP2-binding compound, edonerpic maleate, accelerates motor function recovery from brain damage.
    Science (New York, N.Y.), 2018, 04-06, Volume: 360, Issue:6384

    Topics: Animals; Brain Injuries; Intercellular Signaling Peptides and Proteins; Male; Maleates; Mice; Mice, Knockout; Mice, Mutant Strains; Motor Cortex; Nerve Tissue Proteins; Neuronal Plasticity; Neuroprotection; Quality of Life; Receptors, AMPA; Recovery of Function; Stroke; Thiophenes

2018
Angiotensin receptor (AT2R) agonist C21 prevents cognitive decline after permanent stroke in aged animals-A randomized double- blind pre-clinical study.
    Behavioural brain research, 2019, 02-01, Volume: 359

    Topics: Administration, Oral; Aging; Animals; Body Weight; Cognitive Dysfunction; Disease Models, Animal; Double-Blind Method; Drug Evaluation, Preclinical; Male; Motor Activity; Nootropic Agents; Random Allocation; Rats, Wistar; Receptor, Angiotensin, Type 2; Recovery of Function; Stroke; Sulfonamides; Thiophenes; Time Factors

2019
Safety and efficacy of Rotigotine in hospedalized patients with Vascular Parkinsonism aged 75 and older: effects on movement, praxis capacities, time-space orientation, quality of life and adherence to medical therapy.
    Acta bio-medica : Atenei Parmensis, 2019, 05-23, Volume: 90, Issue:2

    Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Brain Ischemia; Cognition; Dopamine Agonists; Female; Geriatric Assessment; Hospitalization; Humans; Inpatients; Male; Movement; Parkinson Disease, Secondary; Patient Safety; Prospective Studies; Quality of Life; Risk Assessment; Sampling Studies; Severity of Illness Index; Stroke; Tetrahydronaphthalenes; Thiophenes; Time Perception; Transdermal Patch; Treatment Outcome

2019
Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice.
    Journal of molecular medicine (Berlin, Germany), 2019, Volume: 97, Issue:8

    Topics: Animals; Brain Ischemia; Disease Models, Animal; Mice; Oxazoles; PPAR alpha; PPAR gamma; Stroke; Thiophenes

2019
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
    Hospital practice (1995), 2013, Volume: 41, Issue:1

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin

2013
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
    Stroke, 2013, Volume: 44, Issue:6

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Humans; Markov Chains; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin

2013
Involvement of matrix metalloproteinases-2 and -9 in the formation of a lacuna-like cerebral cavity.
    Journal of neuroscience research, 2013, Volume: 91, Issue:7

    Topics: Analysis of Variance; Animals; CD11b Antigen; Disease Models, Animal; Ectodysplasins; Gene Expression Regulation, Enzymologic; Glial Fibrillary Acidic Protein; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Microglia; Minocycline; Phenylalanine; Protease Inhibitors; Rats; Rats, Wistar; Stroke; Stroke, Lacunar; Thiophenes; Time Factors

2013
[Stroke prevention in atrial fibrillation : old and new anticoagulants].
    Herz, 2013, Volume: 38, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K

2013
Conventional and new oral anticoagulants in the treatment of chest disease and its complications.
    American journal of respiratory and critical care medicine, 2013, Aug-15, Volume: 188, Issue:4

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Practice Guidelines as Topic; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K

2013
Summaries for patients. Rivaroxaban in patients transitioned from vitamin K antagonist therapy.
    Annals of internal medicine, 2013, Jun-18, Volume: 158, Issue:12

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin

2013
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Patient Safety; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin

2013
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Complications; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin

2013
[Comparison of the therapeutic effect of the Warfarin and Rivaroksaban among the patients with not-valuate fibrillation of atrium].
    Georgian medical news, 2013, Issue:219

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin

2013
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Journal of medical economics, 2013, Volume: 16, Issue:9

    Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Savings; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Utilization; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; United States; Warfarin

2013
The J-ROCKET AF study: a matter of ethnicity or a matter of weight?
    Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:10

    Topics: Anticoagulants; Atrial Fibrillation; Embolism; Female; Humans; Male; Morpholines; Stroke; Thiophenes; Warfarin

2013
The J-ROCKET AF Study: a matter of ethnicity or a matter of weight? Reply.
    Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:10

    Topics: Anticoagulants; Atrial Fibrillation; Embolism; Female; Humans; Male; Morpholines; Stroke; Thiophenes; Warfarin

2013
Should the newer oral anticoagulants be withheld from patients with valvular AF?
    Chest, 2013, Volume: 144, Issue:2

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; Humans; International Normalized Ratio; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin

2013
Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
    Journal of medical economics, 2013, Volume: 16, Issue:10

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin

2013
[Differential therapy with the new anticoagulants, 5].
    MMW Fortschritte der Medizin, 2013, May-16, Volume: 155, Issue:9

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Germany; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes

2013
New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
    Irish medical journal, 2013, Volume: 106, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome

2013
Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Fact
    Circulation, 2013, Sep-10, Volume: 128, Issue:11

    Topics: Atrial Fibrillation; Embolism; Factor Xa; Female; Humans; Male; Morpholines; Stroke; Thiophenes; Vitamin K

2013
Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inh
    Circulation, 2013, Sep-10, Volume: 128, Issue:11

    Topics: Atrial Fibrillation; Embolism; Factor Xa; Female; Humans; Male; Morpholines; Stroke; Thiophenes; Vitamin K

2013
The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.
    Cerebrovascular diseases (Basel, Switzerland), 2013, Volume: 36, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin

2013
Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.
    PharmacoEconomics, 2013, Volume: 31, Issue:10

    Topics: Anticoagulants; Atrial Fibrillation; Belgium; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Humans; Markov Chains; Morpholines; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin

2013
Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
    Cardiovascular drugs and therapy, 2014, Volume: 28, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; China; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Models, Economic; Morpholines; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Warfarin

2014
Percutaneous left atrial appendage occlusion with a Watchman device following recurrent stroke on warfarin and rivaroxaban in patient with paroxysmal atrial fibrillation.
    Heart, lung & circulation, 2014, Volume: 23, Issue:2

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Cardiac Catheterization; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin

2014
Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
    Clinical drug investigation, 2014, Volume: 34, Issue:1

    Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Factor Xa Inhibitors; Health Care Costs; Humans; Italy; Markov Chains; Morpholines; Pyrazoles; Pyridones; Quality of Life; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin

2014
Stroke and urosepsis after discontinuation of rivaroxaban.
    International journal of cardiology, 2013, Nov-20, Volume: 169, Issue:5

    Topics: Aged, 80 and over; Anticoagulants; Humans; Male; Morpholines; Rivaroxaban; Sepsis; Stroke; Thiophenes; Urinary Tract Infections

2013
Dissolution of the left atrial appendage thrombus with rivaroxaban therapy.
    Cerebrovascular diseases (Basel, Switzerland), 2013, Volume: 36, Issue:4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Female; Humans; Male; Morpholines; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thrombosis; Treatment Outcome

2013
Successful intravenous thrombolysis in acute ischaemic stroke in a patient on rivaroxaban treatment.
    Thrombosis and haemostasis, 2014, Mar-03, Volume: 111, Issue:3

    Topics: Administration, Intravenous; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; Contraindications; Endovascular Procedures; Female; Fibrinolytic Agents; Humans; Ischemia; Middle Cerebral Artery; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome

2014
[Prevention and therapy of thromboembolism: rivaroxaban - better outcome - risk profile as standard therapy].
    MMW Fortschritte der Medizin, 2013, Sep-12, Volume: 155, Issue:15

    Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Drug Substitution; Factor Xa Inhibitors; Humans; Morpholines; Phenprocoumon; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Warfarin

2013
New oral anticoagulants: an emergency department overview.
    Emergency medicine Australasia : EMA, 2013, Volume: 25, Issue:6

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Humans; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis

2013
[How to properly use warfarin and new anticoagulants].
    Rinsho shinkeigaku = Clinical neurology, 2013, Volume: 53, Issue:11

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Humans; International Normalized Ratio; Morpholines; Practice Guidelines as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin

2013
New oral anticoagulants: their role and future.
    Clinical medicine (London, England), 2013, Volume: 13 Suppl 6

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin

2013
Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2014, Volume: 34, Issue:3

    Topics: Animals; Anticoagulants; Blood-Brain Barrier; Brain Ischemia; Cerebral Hemorrhage; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Morpholines; Rats; Rats, Wistar; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy; Time Factors

2014
Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
    Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Automation, Laboratory; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Equipment and Supplies; Factor VII; Hemorrhage; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Stroke; Thiophenes; Thrombelastography; Thrombin; Thrombin Time; Venous Thrombosis; Withholding Treatment

2014
Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke.
    Stroke, 2014, Volume: 45, Issue:3

    Topics: Aged; Anticoagulants; Blood Coagulation; Factor XI; Female; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombelastography; Thrombolytic Therapy

2014
The risk of infection with new oral anticoagulants: a meta-analysis.
    International journal of cardiology, 2014, Mar-01, Volume: 172, Issue:1

    Topics: Anticoagulants; Humans; Male; Morpholines; Sepsis; Stroke; Thiophenes; Urinary Tract Infections

2014
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Journal of the American College of Cardiology, 2014, Mar-25, Volume: 63, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Combined Modality Therapy; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Assessment; Severity of Illness Index; Stents; Stroke; Survival Rate; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome

2014
Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Clinical therapeutics, 2014, Feb-01, Volume: 36, Issue:2

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Markov Chains; Models, Economic; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome

2014
The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke.
    Neuropharmacology, 2014, Volume: 81

    Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Brain Infarction; Brain Ischemia; CD11b Antigen; Cerebrovascular Circulation; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin-1; Glial Fibrillary Acidic Protein; Imidazoles; Male; Nitric Oxide Synthase Type II; Peroxidase; Pyridines; Rats; Rats, Sprague-Dawley; Stroke; Sulfonamides; Thiophenes; Time Factors

2014
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Survival Analysis; Thiazoles; Thiophenes; Treatment Outcome

2014
Secondary hematoma expansion in intracerebral hemorrhage during rivaroxaban therapy.
    The American journal of emergency medicine, 2014, Volume: 32, Issue:8

    Topics: Aged; Anticoagulants; Brain; Cerebral Hemorrhage; Fatal Outcome; Female; Hematoma, Subdural, Intracranial; Humans; Morpholines; Neuroimaging; Rivaroxaban; Stroke; Thiophenes; Tomography, X-Ray Computed

2014
Spontaneus splenic rupture in a patient treated with rivaroxaban.
    The American journal of emergency medicine, 2014, Volume: 32, Issue:8

    Topics: Abdominal Pain; Aged; Anticoagulants; Atrial Fibrillation; Emergency Service, Hospital; Humans; Male; Morpholines; Rivaroxaban; Rupture, Spontaneous; Shock, Hemorrhagic; Splenic Diseases; Stroke; Thiophenes

2014
Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
    Current medical research and opinion, 2014, Volume: 30, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Propensity Score; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin; Young Adult

2014
Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
    PharmacoEconomics, 2014, Volume: 32, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Humans; Markov Chains; Models, Statistical; Morpholines; Norway; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin

2014
Reduced smoke-like echo and resolved thrombus in the left atrium with rivaroxaban therapy in an acute cardioembolic stroke patient.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:6

    Topics: Aged; Echocardiography, Transesophageal; Embolism; Factor Xa Inhibitors; Heart Atria; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Treatment Outcome

2014
Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?
    Current medical research and opinion, 2014, Volume: 30, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Databases, Factual; Female; Hospital Costs; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Morpholines; Propensity Score; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin; Young Adult

2014
Stroke prevention in Asian patients with atrial fibrillation.
    Stroke, 2014, Volume: 45, Issue:6

    Topics: Anticoagulants; Asian People; Female; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes

2014
Perioperative management of patients on new oral anticoagulants.
    The British journal of surgery, 2014, Volume: 101, Issue:7

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Elective Surgical Procedures; Emergencies; Half-Life; Hemorrhage; Humans; Medication Adherence; Morpholines; Preoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Time Factors; Warfarin

2014
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke in a patient treated with rivaroxaban.
    Clinical neurology and neurosurgery, 2014, Volume: 122

    Topics: Aged, 80 and over; Brain Ischemia; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Male; Morpholines; Polypharmacy; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome

2014
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Journal of medical economics, 2014, Volume: 17, Issue:8

    Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comparative Effectiveness Research; Cost-Benefit Analysis; Dabigatran; Factor Xa Inhibitors; Female; France; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin

2014
Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.
    The American journal of medicine, 2014, Volume: 127, Issue:11

    Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Drug Utilization Review; Factor Xa Inhibitors; Fees, Pharmaceutical; Female; Humans; Income; Male; Middle Aged; Morpholines; Multivariate Analysis; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Sex Factors; Stroke; Thiophenes; United States; Vitamin K; Warfarin; Young Adult

2014
Direct oral anticoagulants in atrial fibrillation.
    Seminars in hematology, 2014, Volume: 51, Issue:2

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin

2014
Chymase inhibition improves vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats.
    Journal of hypertension, 2014, Volume: 32, Issue:8

    Topics: Animals; Body Weight; Chymases; Endothelium, Vascular; Hypertension; Male; Matrix Metalloproteinase 9; Myocardium; Rats; Rats, Inbred SHR; Renin; RNA, Messenger; Stroke; Sulfonamides; Systole; Thiophenes

2014
Atrial fibrillation and stroke prevention in aging patients: what's good can be even better.
    Circulation, 2014, Jul-08, Volume: 130, Issue:2

    Topics: Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin

2014
Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation.
    Current medical research and opinion, 2014, Volume: 30, Issue:12

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Databases, Factual; Female; Humans; Male; Medication Adherence; Middle Aged; Morpholines; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin

2014
New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
    Clinical pharmacology and therapeutics, 2014, Volume: 96, Issue:1

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP2C9; Dabigatran; Factor Xa Inhibitors; Genotype; Humans; Morpholines; Pharmacogenetics; Polymorphism, Genetic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Vitamin K Epoxide Reductases; Warfarin

2014
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
    Internal medicine journal, 2014, Volume: 44, Issue:6

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Blood Loss, Surgical; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Elective Surgical Procedures; Emergencies; Hematoma, Epidural, Spinal; Hemorrhage; Humans; Kidney Diseases; Liver Diseases; Morpholines; Patient Selection; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombophilia

2014
Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Vitamin K; Warfarin

2014
Rivaroxaban and apixaban reduce hemorrhagic transformation after thrombolysis by protection of neurovascular unit in rat.
    Stroke, 2014, Volume: 45, Issue:8

    Topics: Animals; Anticoagulants; Blood Coagulation; Brain; Brain Ischemia; Fibrinolytic Agents; Intracranial Hemorrhages; Male; Morpholines; Pyrazoles; Pyridones; Rats; Rats, Wistar; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy; Tissue Plasminogen Activator

2014
Atrial fibrillation choices. Picking an anti-clotting drug.
    Mayo Clinic health letter (English ed.), 2014, Volume: 32, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Food-Drug Interactions; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin

2014
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
    Current medical research and opinion, 2014, Volume: 30, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; United States

2014
A case of rivaroxaban associated intracranial hemorrhage.
    The western journal of emergency medicine, 2014, Volume: 15, Issue:4

    Topics: Aged, 80 and over; Atrial Fibrillation; Factor Xa Inhibitors; Fatal Outcome; Humans; Intracranial Hemorrhages; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes

2014
Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin.
    Stroke, 2014, Volume: 45, Issue:9

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Risk; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin

2014
Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
    Thrombosis and haemostasis, 2014, Volume: 112, Issue:5

    Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Drug Substitution; Female; Humans; International Normalized Ratio; Lupus Erythematosus, Systemic; Male; Mesenteric Veins; Middle Aged; Morpholines; Portal Vein; Recurrence; Retrospective Studies; Rivaroxaban; Splenic Vein; Stroke; Thiophenes; Thromboembolism; Thrombophilia; Treatment Failure; Venous Thrombosis; Warfarin

2014
Intravenous thrombolysis in stroke patients receiving rivaroxaban.
    European journal of neurology, 2014, Volume: 21, Issue:1

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy

2014
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
    Journal of medical economics, 2014, Volume: 17, Issue:11

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Health Expenditures; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin

2014
[The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China].
    Zhonghua nei ke za zhi, 2014, Volume: 53, Issue:5

    Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; China; Comorbidity; Diabetes Mellitus; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Hypertension; Incidence; Inpatients; Male; Morpholines; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin

2014
[New oral anticoagulants are as safe in elderly patients as conventional drugs].
    Praxis, 2014, Aug-20, Volume: 103, Issue:17

    Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Treatment Outcome

2014
Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
    Stroke, 2014, Volume: 45, Issue:10

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin

2014
Revascularization for acute ischemic stroke is safe for rivaroxaban users.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:9

    Topics: Aged, 80 and over; Brain Ischemia; Cerebral Revascularization; Factor Xa Inhibitors; Female; Humans; Infarction, Middle Cerebral Artery; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombectomy; Tissue Plasminogen Activator

2014
[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
    Kardiologiia, 2014, Volume: 54, Issue:7

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Models, Statistical; Morpholines; Myocardial Infarction; Prognosis; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Russia; Stroke; Thiophenes; Warfarin

2014
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2015, Volume: 17, Issue:2

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Denmark; Female; Heart Failure; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Myocardial Ischemia; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Registries; Renal Insufficiency, Chronic; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin

2015
Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient.
    Journal of the neurological sciences, 2014, Nov-15, Volume: 346, Issue:1-2

    Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes

2014
Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies.
    Hospital practice (1995), 2014, Volume: 42, Issue:3

    Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Length of Stay; Male; Middle Aged; Morpholines; Retrospective Studies; Rivaroxaban; Socioeconomic Factors; Stroke; Thiophenes; Warfarin

2014
Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
    Cardiovascular drugs and therapy, 2014, Volume: 28, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin

2014
Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:6

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Coumarins; Dabigatran; Humans; Markov Chains; Middle Aged; Morpholines; Netherlands; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; United Kingdom

2014
Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
    Circulation, 2014, Oct-21, Volume: 130, Issue:17

    Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Thiophenes; Unnecessary Procedures; Warfarin

2014
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial.
    BMC family practice, 2014, Oct-25, Volume: 15

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Family Practice; Female; Germany; Guideline Adherence; Heart Diseases; Heart Valve Prosthesis; Humans; International Normalized Ratio; Male; Mass Screening; Middle Aged; Morpholines; Practice Guidelines as Topic; Process Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Thrombosis; Venous Thromboembolism

2014
Help prevent Afib-related stroke. New anticoagulants for atrial fibrillation prove as effective, or even better than, warfarin--and easier to use.
    DukeMedicine healthnews, 2014, Volume: 20, Issue:9

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin

2014
Acute thrombocytopenia after initiating anticoagulation with rivaroxaban.
    Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:21

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Humans; Intracranial Hemorrhages; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombocytopenia; Warfarin

2014
A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2014, Volume: 41, Issue:3

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Cryosurgery; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Morpholines; Retrospective Studies; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin

2014
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
    Canadian family physician Medecin de famille canadien, 2014, Volume: 60, Issue:11

    Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Family Practice; Hemorrhage; Humans; Morpholines; Preoperative Care; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Time Factors; Venous Thromboembolism

2014
ACP Journal Club: in nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age.
    Annals of internal medicine, 2014, Nov-18, Volume: 161, Issue:10

    Topics: Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Stroke; Thiophenes; Vitamin K; Warfarin

2014
[Rivaroxaban in non valvular atrial fibrillation: subgroups analysis].
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2014, Volume: 82, Issue:1

    Topics: Atrial Fibrillation; Electric Countershock; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes

2014
Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
    American heart journal, 2015, Volume: 169, Issue:1

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin

2015
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
    The American journal of gastroenterology, 2015, Volume: 110, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Ischemic Attack, Transient; Longitudinal Studies; Male; Middle Aged; Morpholines; Patient Readmission; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Venous Thrombosis; Warfarin; Withholding Treatment

2015
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
    The Annals of pharmacotherapy, 2015, Volume: 49, Issue:3

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin

2015
[Retrospective study about 73 consecutive patients treated by direct oral anticoagulant and admitted to an emergency room].
    Journal des maladies vasculaires, 2015, Volume: 40, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Emergency Service, Hospital; Female; France; Hemorrhage; History, Ancient; Hospitalization; Humans; Male; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes

2015
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
    Circulation, 2015, Mar-17, Volume: 131, Issue:11

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Drug Utilization; Female; Hemorrhage; Hospitalization; Humans; Kidney; Kidney Failure, Chronic; Male; Matched-Pair Analysis; Middle Aged; Morpholines; Poisson Distribution; Practice Patterns, Physicians'; Renal Dialysis; Retrospective Studies; Risk; Rivaroxaban; Stroke; Thiophenes; Warfarin

2015
Web Exclusives. The consult guys--too close for comfort? For how long must I stop this anticoagulant for an epidural?
    Annals of internal medicine, 2015, 01-20, Volume: 162, Issue:2

    Topics: Adrenal Cortex Hormones; Aged; Anticoagulants; Drug Administration Schedule; Female; Hemorrhage; Humans; Injections, Epidural; Morpholines; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin; Withholding Treatment

2015
Response.
    Canadian family physician Medecin de famille canadien, 2015, Volume: 61, Issue:1

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Stroke; Thiophenes; Venous Thromboembolism

2015
Well-managed warfarin is superior to NOACs.
    Canadian family physician Medecin de famille canadien, 2015, Volume: 61, Issue:1

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Stroke; Thiophenes; Venous Thromboembolism

2015
Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit).
    The American journal of cardiology, 2015, Mar-01, Volume: 115, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Dabigatran; Hemorrhage; Humans; Male; Medical Audit; Morpholines; Predictive Value of Tests; Primary Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin

2015
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in
    Lancet (London, England), 2015, Jun-13, Volume: 385, Issue:9985

    Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Death, Sudden; Diabetes Mellitus; Digoxin; Factor Xa Inhibitors; Female; Heart Failure; Heart Rate; Humans; Intracranial Embolism; Male; Morpholines; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Rivaroxaban; Sex Distribution; Stroke; Thiophenes; Vitamin K; Warfarin

2015
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
    Circulation, 2015, Apr-21, Volume: 131, Issue:16

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Female; Hemorrhage; Humans; Kidney Diseases; Kidney Function Tests; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia

2015
The shh signaling pathway is upregulated in multiple cell types in cortical ischemia and influences the outcome of stroke in an animal model.
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Animals; Behavior, Animal; Brain Ischemia; Cerebral Cortex; Cyclohexylamines; Hedgehog Proteins; Male; Mice; Signal Transduction; Stroke; Tamoxifen; Thiophenes

2015
[Prevention and emergency measures].
    MMW Fortschritte der Medizin, 2015, Apr-16, Volume: 157, Issue:7

    Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome

2015
Rivaroxaban 10mg/d in severe renal failure does not prevent ischemic events in premorbid neurologic disease.
    Neurologia i neurochirurgia polska, 2015, Volume: 49, Issue:3

    Topics: Aged, 80 and over; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Morpholines; Recurrence; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes

2015
[The X-VeRT study].
    Giornale italiano di cardiologia (2006), 2015, Volume: 16, Issue:6

    Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Electric Countershock; Embolism; Factor Xa Inhibitors; Heart Diseases; Hemorrhage; Humans; International Normalized Ratio; Middle Aged; Morpholines; Multicenter Studies as Topic; Myocardial Infarction; Prospective Studies; Randomized Controlled Trials as Topic; Research Design; Risk; Rivaroxaban; Stroke; Thiophenes; Thrombophilia; Time Factors; Treatment Outcome; Vitamin K; Warfarin

2015
Sphingosine-1-Phosphate Receptor-1 Selective Agonist Enhances Collateral Growth and Protects against Subsequent Stroke.
    PloS one, 2015, Volume: 10, Issue:9

    Topics: Animals; Dimethyl Sulfoxide; Disease Models, Animal; Endothelial Cells; Male; Mice; Oxadiazoles; Receptors, Lysosphingolipid; Sphingosine-1-Phosphate Receptors; Stroke; Thiophenes; Time Factors

2015
An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes.
    Thrombosis research, 2015, Volume: 136, Issue:6

    Topics: Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Ticlopidine

2015
Response to the letter concerning the article "Rivaroxaban in secondary cardiogenic stroke prevention: two-year single-centre experience based on follow-up of 209 patients".
    Kardiologia polska, 2016, Volume: 74, Issue:5

    Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Follow-Up Studies; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Treatment Outcome; Warfarin

2016
3H-1,2-Dithiole-3-thione as a novel therapeutic agent for the treatment of ischemic stroke through Nrf2 defense pathway.
    Brain, behavior, and immunity, 2017, Volume: 62

    Topics: Animals; Antioxidants; Brain Ischemia; Disease Models, Animal; Infarction, Middle Cerebral Artery; Mice; NF-E2-Related Factor 2; Reactive Oxygen Species; Signal Transduction; Stroke; Thiones; Thiophenes

2017
Sleep disorders and neuromuscular diseases.
    Reviews in neurological diseases, 2008,Summer, Volume: 5, Issue:3

    Topics: Administration, Cutaneous; Brain Injuries; Continuous Positive Airway Pressure; Copper; Diabetic Neuropathies; Dopamine Agonists; Humans; Ischemic Attack, Transient; Myasthenia Gravis; Neuromuscular Diseases; Peripheral Nervous System Diseases; Restless Legs Syndrome; Sleep Apnea Syndromes; Sleep Wake Disorders; Stroke; Tetrahydronaphthalenes; Thiophenes

2008
Hemodynamic and cardiac effects of chronic eprosartan and moxonidine therapy in stroke-prone spontaneously hypertensive rats.
    Hypertension (Dallas, Tex. : 1979), 2009, Volume: 53, Issue:5

    Topics: Acrylates; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Heart Rate; Hypertension; Imidazoles; Male; Nitric Oxide Synthase Type III; Phosphorylation; Rats; Rats, Inbred SHR; Stroke; Thiophenes; Ventricular Function, Left

2009
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
    Circulation, 2009, May-19, Volume: 119, Issue:19

    Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cardiovascular Diseases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Female; Genotype; Humans; Male; Microsomes, Liver; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stroke; Thiophenes; Treatment Outcome; Young Adult

2009
Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
    Expert review of cardiovascular therapy, 2009, Volume: 7, Issue:5

    Topics: Acrylates; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Humans; Hypertension; Imidazoles; Ischemic Attack, Transient; Male; Nitrendipine; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Thiophenes

2009
Potent agonists of the Hedgehog signaling pathway.
    Bioorganic & medicinal chemistry letters, 2009, Aug-01, Volume: 19, Issue:15

    Topics: Administration, Oral; Animals; Carboxylic Acids; Cell Line; Chemistry, Pharmaceutical; Drug Design; Hedgehog Proteins; Humans; Mice; Models, Biological; Models, Chemical; Stroke; Structure-Activity Relationship; Thiophenes

2009
Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2009, Volume: 12, Issue:6

    Topics: Acrylates; Antihypertensive Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Enalapril; Europe; Geography; Humans; Hypertension; Imidazoles; Male; Meta-Analysis as Topic; Middle Aged; Monte Carlo Method; Nitrendipine; Primary Prevention; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Secondary Prevention; Stroke; Thiophenes

2009
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire international, 2009, Volume: 18, Issue:103

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Europe; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Recurrence; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome

2009
P2Y12 inhibitors: thienopyridines and direct oral inhibitors.
    Hamostaseologie, 2009, Volume: 29, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stroke; Thiophenes; Ticagrelor

2009
Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats.
    Stroke, 2010, Volume: 41, Issue:2

    Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain; Brain Ischemia; Disease Models, Animal; Drug Administration Schedule; Fingolimod Hydrochloride; Immunosuppressive Agents; In Situ Nick-End Labeling; Infarction, Middle Cerebral Artery; Male; MAP Kinase Signaling System; Nerve Degeneration; Neuroprotective Agents; Oxadiazoles; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Stroke; Thiophenes; Treatment Outcome

2010
Duloxetine related hypersexuality: a case report.
    Progress in neuro-psychopharmacology & biological psychiatry, 2010, Mar-17, Volume: 34, Issue:2

    Topics: Adult; Duloxetine Hydrochloride; Humans; Hypertension; Male; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological; Stroke; Thiophenes

2010
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug
    Circulation, 2010, Jan-05, Volume: 121, Issue:1

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cost-Benefit Analysis; Databases, Factual; Drug Costs; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Life Expectancy; Multicenter Studies as Topic; Myocardial Infarction; Outcome and Process Assessment, Health Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombolytic Therapy; Ticlopidine; United States

2010
Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
    Journal of clinical pharmacology, 2010, Volume: 50, Issue:9

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Blood Coagulation Disorders; Clinical Trials as Topic; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin

2010
Lack of outcome benefit and clopidogrel "resistance." The TRITON trial challenge.
    Thrombosis and haemostasis, 2010, Volume: 103, Issue:2

    Topics: Acute Coronary Syndrome; Clopidogrel; Drug Approval; Drug Resistance; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Survival Analysis; Thiophenes; Ticlopidine; Treatment Outcome

2010
Prasugrel and cancer: an uncertain association or a credible risk that meaningfully alters the benefit-risk balance.
    Archives of internal medicine, 2010, Jun-28, Volume: 170, Issue:12

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Animals; Colorectal Neoplasms; Humans; Incidence; Lung Neoplasms; Mice; Myocardial Infarction; Neoplasms, Experimental; Piperazines; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2 Receptor Antagonists; Risk Factors; Stroke; Thiophenes; United States

2010
[Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial].
    Kardiologiia, 2010, Volume: 50, Issue:6

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome

2010
Is duloxetine useful for central neuropathic pain?
    Pain, 2011, Volume: 152, Issue:2

    Topics: Duloxetine Hydrochloride; Female; Humans; Male; Neuralgia; Spinal Cord Injuries; Stroke; Thiophenes

2011
Factor Xa and thrombin as targets for new oral anticoagulants.
    Thrombosis research, 2011, Volume: 127 Suppl 2

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K

2011
New alternative to warfarin may help reduce stroke risk in patients with AF.
    JAMA, 2011, Jan-05, Volume: 305, Issue:1

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Drug Approval; Humans; Morpholines; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Stroke; Thiophenes; United States; United States Food and Drug Administration; Warfarin

2011
[Rivaroxaban at least as effective as marcumar in stroke prevention].
    MMW Fortschritte der Medizin, 2010, Dec-02, Volume: 152, Issue:48

    Topics: Anticoagulants; Cerebral Infarction; Double-Blind Method; Humans; International Normalized Ratio; Morpholines; Multicenter Studies as Topic; Phenprocoumon; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes

2010
What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
    Thrombosis and haemostasis, 2011, Volume: 105, Issue:4

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes

2011
Prevalence of contraindications and conditions for precaution for prasugrel administration in a real world acute coronary syndrome population.
    Journal of thrombosis and thrombolysis, 2011, Volume: 32, Issue:3

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Diabetes Mellitus; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Prevalence; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Thiophenes

2011
New anticoagulants: moving on from scientific results to clinical implementation.
    Annals of medicine, 2011, Volume: 43, Issue:8

    Topics: Acute Coronary Syndrome; Anticoagulants; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diet; Drug Interactions; Factor VIIa; Factor Xa Inhibitors; Humans; Kidney; Life Style; Monitoring, Physiologic; Morpholines; Recombinant Proteins; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K

2011
A new era for anticoagulation in atrial fibrillation.
    The New England journal of medicine, 2011, Sep-15, Volume: 365, Issue:11

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin

2011
The future of anticoagulant therapy.
    Cardiovascular therapeutics, 2012, Volume: 30, Issue:5

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Dabigatran; Drug Approval; Fibrinolytic Agents; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes

2012
Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase.
    British journal of pharmacology, 2012, Volume: 165, Issue:5

    Topics: Animals; Body Weight; Brain; Disease Models, Animal; Enzyme Inhibitors; Female; HeLa Cells; Humans; Infarction, Middle Cerebral Artery; Isoquinolines; Male; Motor Activity; Neuroprotective Agents; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rats; Rats, Sprague-Dawley; Rats, Wistar; Stroke; Thiophenes; Tumor Cells, Cultured

2012
FDA advisory decision highlights some problems inherent in pragmatic trials.
    JAMA, 2011, Nov-02, Volume: 306, Issue:17

    Topics: Advisory Committees; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Drug Approval; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; United States; United States Food and Drug Administration; Warfarin

2011
Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation.
    Journal of neurology, 2012, Volume: 259, Issue:1

    Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K

2012
Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats.
    Hypertension (Dallas, Tex. : 1979), 2012, Volume: 59, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blood Pressure; Collagen; Disease Models, Animal; Fibronectins; Fibrosis; Hypertension; Losartan; Macrophages; Male; Myocardium; Oxidative Stress; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 2; Stroke; Sulfonamides; Superoxides; Thiophenes; Vascular Stiffness

2012
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Thrombosis and haemostasis, 2012, Volume: 107, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Cohort Studies; Computer Simulation; Dabigatran; Decision Making, Computer-Assisted; Denmark; Humans; Intracranial Hemorrhages; Morpholines; Population Groups; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin

2012
Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2012, Volume: 23 Suppl 1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium; Cardiovascular Diseases; Consensus; Denosumab; Dietary Supplements; Diphosphonates; Female; Humans; Male; Middle Aged; Muscle, Skeletal; Neoplasms; Organometallic Compounds; Osteoporosis; Selective Estrogen Receptor Modulators; Stroke; Thiophenes; Vitamin D

2012
New directions in anticoagulation.
    The American journal of medicine, 2012, Volume: 125, Issue:3

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin

2012
Rivaroxaban and recurrent stroke prevention in AF.
    The Lancet. Neurology, 2012, Volume: 11, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Humans; Ischemic Attack, Transient; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin

2012
New antithrombotic drugs: a revolution in stroke management.
    Cardiovascular journal of Africa, 2012, Volume: 23, Issue:2

    Topics: Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Approval; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Monitoring, Physiologic; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin

2012
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
    Journal of medical economics, 2012, Volume: 15, Issue:4

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Control; Dabigatran; Endpoint Determination; Health Expenditures; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; United States; Warfarin

2012
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Journal of the American College of Cardiology, 2012, Aug-21, Volume: 60, Issue:8

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome

2012
Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
    The American journal of cardiology, 2012, Sep-15, Volume: 110, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Humans; Markov Chains; Medicare; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin

2012
Oral anticoagulants for atrial fibrillation: Which one to choose?
    Advance for NPs & PAs, 2012, Volume: 3, Issue:5

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Costs; Drug Substitution; Humans; Morpholines; Pyridines; Rivaroxaban; Stroke; Thiophenes; Warfarin

2012
A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation.
    European heart journal, 2012, Volume: 33, Issue:17

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Drug Costs; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes

2012
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Circulation. Cardiovascular quality and outcomes, 2012, Jul-01, Volume: 5, Issue:4

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin

2012
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
    The American journal of medicine, 2012, Volume: 125, Issue:9

    Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Risk Assessment; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin

2012
New oral anticoagulant in atrial fibrillation: are they comparable?
    International angiology : a journal of the International Union of Angiology, 2012, Volume: 31, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes

2012
Is rivaroxaban safer and more effective than warfarin in patients with atrial fibrillation and stroke or TIA?
    The Lancet. Neurology, 2012, Volume: 11, Issue:8

    Topics: Anticoagulants; Atrial Fibrillation; Humans; Ischemic Attack, Transient; Morpholines; Stroke; Thiophenes; Warfarin

2012
Discovery of a potential anti-ischemic stroke agent: 3-pentylbenzo[c]thiophen-1(3H)-one.
    Journal of medicinal chemistry, 2012, Aug-23, Volume: 55, Issue:16

    Topics: Animals; Antioxidants; Brain; Brain Edema; Brain Infarction; Brain Ischemia; Fibrinolytic Agents; Free Radical Scavengers; Male; Neuroprotective Agents; PC12 Cells; Platelet Aggregation Inhibitors; Rabbits; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Stereoisomerism; Stroke; Structure-Activity Relationship; Thiophenes

2012
Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Judgment; Metformin; Multicenter Studies as Topic; Myocardial Infarction; Observer Variation; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Process Assessment, Health Care; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Ticagrelor

2012
J-ROCKET AF trial increased expectation of lower-dose rivaroxaban made for Japan.
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:9

    Topics: Anticoagulants; Atrial Fibrillation; Embolism; Female; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin

2012
New anticoagulants.
    British dental journal, 2012, Volume: 213, Issue:3

    Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin

2012
Danger ahead: watch out for indirect comparisons!
    Journal of the American College of Cardiology, 2012, Aug-21, Volume: 60, Issue:8

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes

2012
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Embolism; Humans; Markov Chains; Models, Economic; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin

2012
Rivaroxaban and other novel anticoagulants for stroke prevention in atrial fibrillation: time to embrace the future.
    Heart (British Cardiac Society), 2013, Volume: 99, Issue:6

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Female; Forecasting; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes

2013
How big is the impact of the warfarin cost on the cost-effectiveness of rivaroxoban for stroke prevention in atrial fibrillation?
    The American journal of cardiology, 2012, Nov-01, Volume: 110, Issue:9

    Topics: Anticoagulants; Atrial Fibrillation; Humans; Morpholines; Stroke; Thiophenes; Warfarin

2012
Rivaroxaban in acute coronary syndromes and atrial fibrillation: rivaroxaban shown to reduce cardiovascular deaths in STEMI patients.
    Cardiovascular journal of Africa, 2012, Volume: 23, Issue:9

    Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Electrocardiography; Expert Testimony; Humans; Morpholines; Myocardial Infarction; Practice Guidelines as Topic; Rivaroxaban; Stroke; Survival Analysis; Thiophenes; Treatment Outcome

2012
[Introduction].
    Revista clinica espanola, 2012, Volume: 212 Suppl 1

    Topics: Acenocoumarol; Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Thrombosis; Warfarin

2012
[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes].
    Revista clinica espanola, 2012, Volume: 212 Suppl 1

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin

2012
[Rivaroxaban versus warfarin: results of the ROCKET study].
    Ideggyogyaszati szemle, 2012, Sep-30, Volume: 65, Issue:9-10

    Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Double-Blind Method; Humans; Morpholines; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Renal Insufficiency; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Treatment Outcome; Warfarin

2012
Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.
    BMJ (Clinical research ed.), 2012, Nov-05, Volume: 345

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Male; Morpholines; Pharmacovigilance; Primary Prevention; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin

2012
New oral anticoagulants.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2013, Mar-05, Volume: 185, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Canada; Contraindications; Dabigatran; Drug Dosage Calculations; Drug Interactions; Humans; Morpholines; Postoperative Complications; Pyridines; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis

2013
[New anticoagulants: better knowledge, better prescriptions].
    Revue medicale suisse, 2012, Jan-18, Volume: 8, Issue:324

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K

2012
Reply: To PMID 22575324.
    Journal of the American College of Cardiology, 2013, Feb-05, Volume: 61, Issue:5

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Stroke; Thiophenes

2013
Lack of stroke subtype information may hinder indirect comparison between the ROCKET-AF and other trials of new oral anticoagulants.
    Journal of the American College of Cardiology, 2013, Feb-05, Volume: 61, Issue:5

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Stroke; Thiophenes

2013
Transitions of care in anticoagulation management for patients with atrial fibrillation.
    Hospital practice (1995), 2012, Volume: 40, Issue:4

    Topics: Administration, Oral; Aftercare; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Continuity of Patient Care; Dabigatran; Drug Monitoring; Drug Substitution; Emergencies; Hemorrhage; Humans; Morpholines; Patient Education as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin

2012
"R" for "renal" and for "risk": refining risk stratification for stroke in atrial fibrillation.
    Circulation, 2013, Jan-15, Volume: 127, Issue:2

    Topics: Atrial Fibrillation; Embolism; Factor Xa; Female; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Vitamin K

2013
Reconsideration of anticoagulant therapy in Japanese patients with atrial fibrillation and moderate renal impairment.
    Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:3

    Topics: Anticoagulants; Asian People; Atrial Fibrillation; Female; Humans; Male; Morpholines; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes

2013
Discontinuation of rivaroxaban: filling in the gaps.
    Journal of the American College of Cardiology, 2013, Feb-12, Volume: 61, Issue:6

    Topics: Atrial Fibrillation; Blood Coagulation; Female; Humans; Male; Morpholines; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin

2013
[Therapy of hypertension. Why the systolic value is decisive].
    MMW Fortschritte der Medizin, 2002, Jun-06, Volume: 144, Issue:23

    Topics: Acrylates; Antihypertensive Agents; Coronary Disease; Enalapril; Humans; Hypertension; Imidazoles; Risk Factors; Stroke; Systole; Thiophenes; Treatment Outcome

2002
Analysis of recent papers in hypertension. An angiotensin receptor blocker is more effective than a calcium channel blocker in secondary stroke prevention.
    Journal of clinical hypertension (Greenwich, Conn.), 2005, Volume: 7, Issue:8

    Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Humans; Hypertension; Imidazoles; Nitrendipine; Randomized Controlled Trials as Topic; Stroke; Survival Rate; Thiophenes

2005
Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine?
    Stroke, 2006, Volume: 37, Issue:6

    Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Humans; Imidazoles; Nitrendipine; Randomized Controlled Trials as Topic; Stroke; Thiophenes

2006
Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine?
    Nature clinical practice. Neurology, 2006, Volume: 2, Issue:1

    Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Follow-Up Studies; Humans; Imidazoles; Multicenter Studies as Topic; Nitrendipine; Prospective Studies; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Treatment Outcome

2006
[Not all antihypertensive agents protect equally well].
    MMW Fortschritte der Medizin, 2006, Aug-17, Volume: 148, Issue:33-34

    Topics: Acrylates; Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Diuretics; Follow-Up Studies; Humans; Hypertension; Imidazoles; Meta-Analysis as Topic; Nitrendipine; Primary Prevention; Risk Factors; Stroke; Thiophenes; Time Factors

2006
Prasugrel versus clopidogrel.
    The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12

    Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine

2008
For better or for worse: the future of antiplatelet therapy.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Jun-01, Volume: 65, Issue:11

    Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Thrombolytic Therapy; Thrombosis; Ticlopidine

2008
[Stroke prevention. Is there an added value to RAS inhibition?].
    MMW Fortschritte der Medizin, 2000, Feb-10, Volume: 142, Issue:6

    Topics: Acrylates; Animals; Antihypertensive Agents; Humans; Hypertension; Imidazoles; Randomized Controlled Trials as Topic; Rats; Stroke; Thiophenes

2000
Discovery and development of neuronal nitric oxide synthase inhibitors.
    Free radical biology & medicine, 2000, May-15, Volume: 28, Issue:10

    Topics: Animals; Brain Ischemia; Disease Models, Animal; Dogs; Drug Design; Enzyme Inhibitors; Humans; Isoquinolines; Kinetics; Macaca fascicularis; Male; Mice; Neuroprotective Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Rats; Stroke; Tetrahydroisoquinolines; Thiophenes

2000
Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke.
    Stroke, 2000, Volume: 31, Issue:12

    Topics: Animals; Cerebral Hemorrhage; Disease Models, Animal; Fibrinolytic Agents; Humans; Intracranial Embolism; Metalloendopeptidases; Phenylalanine; Protease Inhibitors; Rabbits; Stroke; Thiophenes; Thromboembolism; Tissue Plasminogen Activator

2000
Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2000, Volume: 20, Issue:12

    Topics: Animals; Brain; Brain Ischemia; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred Strains; Mice, Knockout; Neuroprotective Agents; Phenylalanine; Protease Inhibitors; Stroke; Thiophenes; Transcription, Genetic

2000
Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.
    Cardiovascular research, 2001, Volume: 50, Issue:3

    Topics: Acrylates; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Body Weight; Cardiomegaly; Heart Rate; Hypertension; Imidazoles; Kidney; Magnetic Resonance Imaging; Male; Myocardium; Natriuresis; Organ Size; Peptide Fragments; Protein Precursors; Proteinuria; Rats; Rats, Inbred SHR; Stroke; Survival Rate; Thiophenes; Ventricular Remodeling

2001
The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.
    The Journal of pharmacology and experimental therapeutics, 2002, Volume: 301, Issue:1

    Topics: Acrylates; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Blotting, Western; Body Weight; Dietary Fats; Disease Progression; Extracellular Matrix; Fibrinolysin; Gene Expression Regulation; Heart Rate; Hypertension; Imidazoles; Kidney Diseases; Male; Organ Size; Plasminogen Activator Inhibitor 1; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Serine Proteinase Inhibitors; Sodium Chloride, Dietary; Stroke; Thiophenes; Thrombosis

2002